PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
27484838-11	2016	Furthermore, inhibition of JNK by its inhibitor, SP600125, or MEK/Erk signalling by its inhibitor, PD98059, dramatically blocked IGFBP5-enhanced ALP activity and in vitro mineralization in both PDLSCs and WJCMSCs.	pyrazolanthrone	49-57	insulin like growth factor binding protein 5	Homo sapiens	129-135
28450971-8	2017	Changes in methylation levels of CpG sites within AKT3, ATF1, HDAC4, and IGFBP5 were correlated with changes in plasma triglyceride and glucose levels as well as with changes in the ratio of total cholesterol/HDL-cholesterol following the supplementation.	Triglycerides	119-131	insulin like growth factor binding protein 5	Homo sapiens	73-79
28450971-8	2017	Changes in methylation levels of CpG sites within AKT3, ATF1, HDAC4, and IGFBP5 were correlated with changes in plasma triglyceride and glucose levels as well as with changes in the ratio of total cholesterol/HDL-cholesterol following the supplementation.	Glucose	136-143	insulin like growth factor binding protein 5	Homo sapiens	73-79
28450971-8	2017	Changes in methylation levels of CpG sites within AKT3, ATF1, HDAC4, and IGFBP5 were correlated with changes in plasma triglyceride and glucose levels as well as with changes in the ratio of total cholesterol/HDL-cholesterol following the supplementation.	Cholesterol	197-208	insulin like growth factor binding protein 5	Homo sapiens	73-79
28450971-8	2017	Changes in methylation levels of CpG sites within AKT3, ATF1, HDAC4, and IGFBP5 were correlated with changes in plasma triglyceride and glucose levels as well as with changes in the ratio of total cholesterol/HDL-cholesterol following the supplementation.	Cholesterol	213-224	insulin like growth factor binding protein 5	Homo sapiens	73-79
27893412-8	2017	Importantly, selinexor inhibited insulin-like growth factor 1 (IGF1) activation of IGF-1R/AKT pathway through upregulation of insulin-like growth factor binding protein 5 (IGFBP5).	selinexor	13-22	insulin like growth factor binding protein 5	Homo sapiens	126-170
27893412-8	2017	Importantly, selinexor inhibited insulin-like growth factor 1 (IGF1) activation of IGF-1R/AKT pathway through upregulation of insulin-like growth factor binding protein 5 (IGFBP5).	selinexor	13-22	insulin like growth factor binding protein 5	Homo sapiens	172-178
27893412-9	2017	Further, overexpression and knockdown experiments showed that IGFBP5 acts as a tumor suppressor and its expression was restored upon selinexor treatment of liposarcoma cells.	selinexor	133-142	insulin like growth factor binding protein 5	Homo sapiens	62-68
27893412-11	2017	Overall, our study showed that selinexor treatment restored tumor suppressive function of IGFBP5 and inhibited aurora kinase A and B in liposarcoma cells supporting the usefulness of selinexor as a potential therapeutic strategy for the treatment of this cancer.	selinexor	31-40	insulin like growth factor binding protein 5	Homo sapiens	90-96
27484838-11	2016	Furthermore, inhibition of JNK by its inhibitor, SP600125, or MEK/Erk signalling by its inhibitor, PD98059, dramatically blocked IGFBP5-enhanced ALP activity and in vitro mineralization in both PDLSCs and WJCMSCs.	2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one	99-106	insulin like growth factor binding protein 5	Homo sapiens	129-135
26557016-0	2015	Pitavastatin Regulates Ang II Induced Proliferation and Migration via IGFBP-5 in VSMC.	pitavastatin	0-12	insulin like growth factor binding protein 5	Homo sapiens	70-77
26515727-4	2015	Further analyses revealed that MSCs and CAFs coordinately induce these changes by triggering the downregulation of IGFBP5.	cafs	40-44	insulin like growth factor binding protein 5	Homo sapiens	115-121
26515727-5	2015	Loss of IGFBP5 in MCF-7 cells was an early and long-lasting event in response to MSCs and CAFs and was accompanied by growth stimulation both in the absence and presence of fulvestrant.	cafs	90-94	insulin like growth factor binding protein 5	Homo sapiens	8-14
26515727-10	2015	In conclusion, our data suggest that, by targeting IGFBP5 expression in ERalpha-positive breast cancer cells, such as MCF-7 cells, MSCs and CAFs are able to orchestrate a variety of events, particularly activation of the PI3K/AKT pathway, upregulation of Bcl-3 expression and desensitization to anti-estrogen.	cafs	140-144	insulin like growth factor binding protein 5	Homo sapiens	51-57
26557016-9	2015	Taken together, our results indicated that Ang II induces IGFBP5 through AT1, ERK1/2, P38, and PI3K signaling pathways, which were inhibited by Pitavastatin.	pitavastatin	144-156	insulin like growth factor binding protein 5	Homo sapiens	58-64
25524807-0	2015	The role of IGFBP-5 in mediating the anti-proliferation effect of tetrandrine in human colon cancer cells.	tetrandrine	66-77	insulin like growth factor binding protein 5	Homo sapiens	12-19
25983620-10	2015	Further studies are needed to clarify the expressional regulation of IGFBP5 by miR-140-5p.	mir-140	79-86	insulin like growth factor binding protein 5	Homo sapiens	69-75
25524807-8	2015	Tet can downregulate the expression of IGFBP-5 in LoVo cells.	tetrandrine	0-3	insulin like growth factor binding protein 5	Homo sapiens	39-46
25524807-9	2015	Exogenous expression of IGFBP-5 can attenuate the anti-cancer activity of Tet, while IGFBP-5 knockdown potentiates this effect of Tet on LoVo cells.	tetrandrine	74-77	insulin like growth factor binding protein 5	Homo sapiens	24-31
25524807-9	2015	Exogenous expression of IGFBP-5 can attenuate the anti-cancer activity of Tet, while IGFBP-5 knockdown potentiates this effect of Tet on LoVo cells.	tetrandrine	130-133	insulin like growth factor binding protein 5	Homo sapiens	85-92
25524807-10	2015	Tet can inhibit Wnt/beta-catenin signaling transduction, which can be partly reversed by exogenous expression of IGFBP-5, but is enhanced by IGFBP-5 knockdown.	tetrandrine	0-3	insulin like growth factor binding protein 5	Homo sapiens	113-120
25524807-10	2015	Tet can inhibit Wnt/beta-catenin signaling transduction, which can be partly reversed by exogenous expression of IGFBP-5, but is enhanced by IGFBP-5 knockdown.	tetrandrine	0-3	insulin like growth factor binding protein 5	Homo sapiens	141-148
25524807-11	2015	Our results demonstrated that the anticancer activity of Tet in colon cancer cells may be mediated partly by downregulating the expression of IGFBP-5, thus inactivating Wnt/beta-catenin signaling transduction.	tetrandrine	57-60	insulin like growth factor binding protein 5	Homo sapiens	142-149
23576565-8	2013	Similar results were obtained after selection of imatinib-resistant DOG1- and KIT-negative cells derived from parental DOG1 and KIT-positive GIST cells, where a 5,000-fold increase in IGFBP5 mRNA transcripts were documented.	Imatinib Mesylate	49-57	insulin like growth factor binding protein 5	Homo sapiens	184-190
25603050-0	2015	MiR-204-5p suppresses cell proliferation by inhibiting IGFBP5 in papillary thyroid carcinoma.	mir-204-5p	0-10	insulin like growth factor binding protein 5	Homo sapiens	55-61
25603050-5	2015	The results of a luciferase reporter assay showed that miR-204-5p can directly bind to the 3" untranslated region (UTR) of insulin-like growth factor-binding protein 5 (IGFBP5) mRNA, and IGFBP5 overexpression partially reversed the growth-inhibitory effects of miR-204-5p.	mir-204-5p	55-65	insulin like growth factor binding protein 5	Homo sapiens	123-167
25603050-5	2015	The results of a luciferase reporter assay showed that miR-204-5p can directly bind to the 3" untranslated region (UTR) of insulin-like growth factor-binding protein 5 (IGFBP5) mRNA, and IGFBP5 overexpression partially reversed the growth-inhibitory effects of miR-204-5p.	mir-204-5p	55-65	insulin like growth factor binding protein 5	Homo sapiens	169-175
25603050-5	2015	The results of a luciferase reporter assay showed that miR-204-5p can directly bind to the 3" untranslated region (UTR) of insulin-like growth factor-binding protein 5 (IGFBP5) mRNA, and IGFBP5 overexpression partially reversed the growth-inhibitory effects of miR-204-5p.	mir-204-5p	55-65	insulin like growth factor binding protein 5	Homo sapiens	187-193
25603050-5	2015	The results of a luciferase reporter assay showed that miR-204-5p can directly bind to the 3" untranslated region (UTR) of insulin-like growth factor-binding protein 5 (IGFBP5) mRNA, and IGFBP5 overexpression partially reversed the growth-inhibitory effects of miR-204-5p.	mir-204-5p	261-271	insulin like growth factor binding protein 5	Homo sapiens	123-167
25603050-5	2015	The results of a luciferase reporter assay showed that miR-204-5p can directly bind to the 3" untranslated region (UTR) of insulin-like growth factor-binding protein 5 (IGFBP5) mRNA, and IGFBP5 overexpression partially reversed the growth-inhibitory effects of miR-204-5p.	mir-204-5p	261-271	insulin like growth factor binding protein 5	Homo sapiens	169-175
25603050-5	2015	The results of a luciferase reporter assay showed that miR-204-5p can directly bind to the 3" untranslated region (UTR) of insulin-like growth factor-binding protein 5 (IGFBP5) mRNA, and IGFBP5 overexpression partially reversed the growth-inhibitory effects of miR-204-5p.	mir-204-5p	261-271	insulin like growth factor binding protein 5	Homo sapiens	187-193
24157812-5	2014	Osteopontin-a upregulates the levels of glucose in breast cancer cells, likely through STAT3 and its transcriptional targets apolipoprotein D and IGFBP5.	Glucose	40-47	insulin like growth factor binding protein 5	Homo sapiens	146-152
23527161-12	2013	Moreover, IGFBP-2 and -3 (in MCF-7 cells) and IGFBP-5 (in C2 cells) increase intracellular free calcium concentration by a pertussis toxin sensitive signaling pathway.	Calcium	96-103	insulin like growth factor binding protein 5	Homo sapiens	46-53
22374671-6	2012	We searched for STAT3-downstream molecule(s) responsible for the senescence-inducing activity in the supernatants of stimulated TIG3 and identified IGFBP5 as a major STAT3 mediator, because IGFBP5 was expressed from the early phase through the entire senescence process and was responsible for IL-6/STAT3-induced ROS increase and premature senescence.	Reactive Oxygen Species	313-316	insulin like growth factor binding protein 5	Homo sapiens	148-154
22313597-2	2012	IGFBP5, one of these IGFBPs, has special structural features, including a nuclear transport domain, heparin-binding motif, and IGF/extracellular matrix/acid-labile subunit-binding sites.	Heparin	100-107	insulin like growth factor binding protein 5	Homo sapiens	0-6
22313597-2	2012	IGFBP5, one of these IGFBPs, has special structural features, including a nuclear transport domain, heparin-binding motif, and IGF/extracellular matrix/acid-labile subunit-binding sites.	Heparin	100-107	insulin like growth factor binding protein 5	Homo sapiens	21-27
23053988-3	2012	GH (15 nM) alone or co-treated with ALA increased hepatocytes IGF-I secretion and the expression of GHR and IGFBP1 mRNAs, but down-regulated IGFBP5 mRNA compared with appropriate control across ALA. GH also enhanced the ALA-induced increase in the transcript levels of IGF-II and GHR, but tended to attenuate that of IGFBP4.	alpha-Linolenic Acid	36-39	insulin like growth factor binding protein 5	Homo sapiens	141-147
22328518-5	2012	Using IGFBP5 mutants we demonstrate that the effect is IGF-independent but requires the heparin-binding domain in the C-terminus of IGFBP5.	Heparin	88-95	insulin like growth factor binding protein 5	Homo sapiens	6-12
22328518-5	2012	Using IGFBP5 mutants we demonstrate that the effect is IGF-independent but requires the heparin-binding domain in the C-terminus of IGFBP5.	Heparin	88-95	insulin like growth factor binding protein 5	Homo sapiens	132-138
22374671-6	2012	We searched for STAT3-downstream molecule(s) responsible for the senescence-inducing activity in the supernatants of stimulated TIG3 and identified IGFBP5 as a major STAT3 mediator, because IGFBP5 was expressed from the early phase through the entire senescence process and was responsible for IL-6/STAT3-induced ROS increase and premature senescence.	Reactive Oxygen Species	313-316	insulin like growth factor binding protein 5	Homo sapiens	190-196
20739664-6	2010	GATA6 reduction alone increased basal IGFBP4 and decreased IGFBP5 with both vehicle and cAMP, and GATA4 reduction alone lowered cAMP IGFBP5 levels with cAMP.	Cyclic AMP	128-132	insulin like growth factor binding protein 5	Homo sapiens	133-139
21191810-0	2011	Involvement of IGF binding protein 5 in prostaglandin E(2)-induced cellular senescence in human fibroblasts.	Dinoprostone	40-58	insulin like growth factor binding protein 5	Homo sapiens	15-36
21191810-5	2011	Notably, PGE(2) treatment increased the IGFBP5 protein level.	Prostaglandins E	9-12	insulin like growth factor binding protein 5	Homo sapiens	40-46
21191810-7	2011	Down-regulation of IGFBP5 inhibited PGE(2)-induced cellular senescence.	Dinoprostone	36-42	insulin like growth factor binding protein 5	Homo sapiens	19-25
21191810-8	2011	Taken together, these results suggest that PGE(2) may play an important role in controlling cellular senescence of HDFs through the regulation of IGFBP5 and therefore may contribute to inflammatory disorders associated with aging.	Prostaglandins E	43-46	insulin like growth factor binding protein 5	Homo sapiens	146-152
21210651-4	2011	This peptide, designated AMP-IBP5 (antimicrobial peptide derived from insulin-like growth factor-binding protein 5), showed antimicrobial activity against six of the eight microorganisms tested at concentrations comparable to or lower than those for well-characterized AMPs cathelicidin and beta-defensin-2.	Adenosine Monophosphate	25-28	insulin like growth factor binding protein 5	Homo sapiens	29-33
21210651-4	2011	This peptide, designated AMP-IBP5 (antimicrobial peptide derived from insulin-like growth factor-binding protein 5), showed antimicrobial activity against six of the eight microorganisms tested at concentrations comparable to or lower than those for well-characterized AMPs cathelicidin and beta-defensin-2.	Adenylyl sulfate	269-273	insulin like growth factor binding protein 5	Homo sapiens	29-33
21210651-5	2011	AMP-IBP5 is identical at the amino acid level between human, mouse, rat, pig, and cow.	Adenosine Monophosphate	0-3	insulin like growth factor binding protein 5	Homo sapiens	4-8
22117064-0	2012	Defining the disulfide bonds of insulin-like growth factor-binding protein-5 by tandem mass spectrometry with electron transfer dissociation and collision-induced dissociation.	Disulfides	13-22	insulin like growth factor binding protein 5	Homo sapiens	32-76
22117064-2	2012	IGFBPs are composed of cysteine-rich amino- (N-) and carboxyl- (C-) terminal domains, along with a cysteine-poor central linker segment.	Cysteine	23-31	insulin like growth factor binding protein 5	Homo sapiens	0-6
22117064-2	2012	IGFBPs are composed of cysteine-rich amino- (N-) and carboxyl- (C-) terminal domains, along with a cysteine-poor central linker segment.	Cysteine	99-107	insulin like growth factor binding protein 5	Homo sapiens	0-6
22117064-3	2012	IGFBP-5 is the most conserved IGFBP, and contains 18 cysteines, but only 2 of 9 putative disulfide bonds have been mapped to date.	Cysteine	53-62	insulin like growth factor binding protein 5	Homo sapiens	0-7
22117064-3	2012	IGFBP-5 is the most conserved IGFBP, and contains 18 cysteines, but only 2 of 9 putative disulfide bonds have been mapped to date.	Cysteine	53-62	insulin like growth factor binding protein 5	Homo sapiens	0-5
22117064-5	2012	In addition, in conjunction with ab initio molecular modeling we are able to assign the other 4 disulfide linkages to within a GCGCCXXC motif that is conserved in five IGFBPs.	Disulfides	96-105	insulin like growth factor binding protein 5	Homo sapiens	168-174
22117064-7	2012	Our results not only establish a disulfide bond map of IGFBP-5 but also define a general approach that takes advantage of the specificity of ETD and the scalability of tandem MS, and the predictive power of ab initio molecular modeling to characterize unknown disulfide linkages in proteins.	Disulfides	33-42	insulin like growth factor binding protein 5	Homo sapiens	55-62
22117064-7	2012	Our results not only establish a disulfide bond map of IGFBP-5 but also define a general approach that takes advantage of the specificity of ETD and the scalability of tandem MS, and the predictive power of ab initio molecular modeling to characterize unknown disulfide linkages in proteins.	Disulfides	260-269	insulin like growth factor binding protein 5	Homo sapiens	55-62
20354179-0	2010	Genetic screen identifies insulin-like growth factor binding protein 5 as a modulator of tamoxifen resistance in breast cancer.	Tamoxifen	89-98	insulin like growth factor binding protein 5	Homo sapiens	26-70
20739664-5	2010	IGFBP2 and IGFBP4 mRNAs were increased and IGFBP5 mRNA decreased with vehicle and cAMP treatment under GATA4 plus GATA6 RNAi conditions.	Cyclic AMP	82-86	insulin like growth factor binding protein 5	Homo sapiens	43-49
20739664-6	2010	GATA6 reduction alone increased basal IGFBP4 and decreased IGFBP5 with both vehicle and cAMP, and GATA4 reduction alone lowered cAMP IGFBP5 levels with cAMP.	Cyclic AMP	88-92	insulin like growth factor binding protein 5	Homo sapiens	59-65
20739664-6	2010	GATA6 reduction alone increased basal IGFBP4 and decreased IGFBP5 with both vehicle and cAMP, and GATA4 reduction alone lowered cAMP IGFBP5 levels with cAMP.	Cyclic AMP	128-132	insulin like growth factor binding protein 5	Homo sapiens	133-139
20583135-0	2010	Decreased expression of insulin-like growth factor binding protein-5 during N-(4-hydroxyphenyl)retinamide-induced neuronal differentiation of ARPE-19 human retinal pigment epithelial cells: regulation by CCAAT/enhancer-binding protein.	Fenretinide	76-105	insulin like growth factor binding protein 5	Homo sapiens	24-68
20583135-2	2010	We identified IGFBP5 by microarray analysis as a gene differentially regulated during N-(4-hydroxyphenyl)retinamide (4HPR)-induced neuronal differentiation of human retinal pigment epithelial (RPE) cells.	Fenretinide	86-115	insulin like growth factor binding protein 5	Homo sapiens	14-20
20583135-2	2010	We identified IGFBP5 by microarray analysis as a gene differentially regulated during N-(4-hydroxyphenyl)retinamide (4HPR)-induced neuronal differentiation of human retinal pigment epithelial (RPE) cells.	Fenretinide	117-121	insulin like growth factor binding protein 5	Homo sapiens	14-20
20583135-5	2010	IGFBP5 down-regulation, similar to neuronal differentiation, is mediated by the MAPK pathway since U0126, an inhibitor of MEK1/2, effectively blocked it.	U 0126	99-104	insulin like growth factor binding protein 5	Homo sapiens	0-6
20354179-2	2010	Through a genome-wide RNA interference screen to discover genes responsible for tamoxifen resistance in vitro, we identified insulin-like growth factor binding protein 5 (IGFBP5) as a determinant of drug sensitivity.	Tamoxifen	80-89	insulin like growth factor binding protein 5	Homo sapiens	125-169
20354179-2	2010	Through a genome-wide RNA interference screen to discover genes responsible for tamoxifen resistance in vitro, we identified insulin-like growth factor binding protein 5 (IGFBP5) as a determinant of drug sensitivity.	Tamoxifen	80-89	insulin like growth factor binding protein 5	Homo sapiens	171-177
20354179-3	2010	Specific knockdown of IGFBP5 by retroviral infection with short hairpin RNA-expressing cassette in MCF7 human breast cancer cells (pRS-shIGFBP5) conferred tamoxifen resistance in vitro due to concomitant loss of ERalpha expression and signaling.	Tamoxifen	155-164	insulin like growth factor binding protein 5	Homo sapiens	22-28
20354179-4	2010	IGFBP5 expression was also reduced in MCF7 cells selected for tamoxifen resistance in culture (TAMR).	Tamoxifen	62-71	insulin like growth factor binding protein 5	Homo sapiens	0-6
20354179-4	2010	IGFBP5 expression was also reduced in MCF7 cells selected for tamoxifen resistance in culture (TAMR).	tamr	95-99	insulin like growth factor binding protein 5	Homo sapiens	0-6
20354179-7	2010	IGFBP5 immunohistochemical staining in a cohort of 153 breast cancer patients showed that low IGFBP5 expression was associated with shorter overall survival after tamoxifen therapy.	Tamoxifen	163-172	insulin like growth factor binding protein 5	Homo sapiens	0-6
20354179-7	2010	IGFBP5 immunohistochemical staining in a cohort of 153 breast cancer patients showed that low IGFBP5 expression was associated with shorter overall survival after tamoxifen therapy.	Tamoxifen	163-172	insulin like growth factor binding protein 5	Homo sapiens	94-100
20354179-8	2010	Thus, IGFBP5 warrants investigation as an agent to reverse tamoxifen resistance.	Tamoxifen	59-68	insulin like growth factor binding protein 5	Homo sapiens	6-12
19540231-16	2009	Heparin abolished responses to Vn, IGFBP-5 and non-glycosylated IGFBP-3, but only partially inhibited the response to glycosylated IGFBP-3.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	35-42
19808657-10	2009	AG1024, an IGF-I receptor tyrosine kinase inhibitor, was used to isolate the IGF-I-independent effects of IGFBP-5.	tyrphostin AG 1024	0-6	insulin like growth factor binding protein 5	Homo sapiens	106-113
18602100-5	2008	Heparin inhibited the uptake of the fusion proteins with IGFBP-3 and IGFBP-5, indicating that the delivery pathway is heparin-dependent endocytosis, similar to that of HIV-Tat.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	69-76
19236847-3	2009	We show that this binding is inhibited by IGF-I and that, for IGFBP-5, binding occurs through the C-terminal heparin binding domain of the protein.	Heparin	109-116	insulin like growth factor binding protein 5	Homo sapiens	62-69
19131643-10	2009	IGFBP-5-induced migration was blocked by the MEK1/2 inhibitor U0126, suggesting that IGFBP-5-induced migration occurs via MAPK activation.	U 0126	62-67	insulin like growth factor binding protein 5	Homo sapiens	0-7
19131643-10	2009	IGFBP-5-induced migration was blocked by the MEK1/2 inhibitor U0126, suggesting that IGFBP-5-induced migration occurs via MAPK activation.	U 0126	62-67	insulin like growth factor binding protein 5	Homo sapiens	85-92
18957933-2	2009	We have shown earlier that the IGFBP5 gene was downregulated in the adipose tissue after 12-week carbohydrate diet with low insulinemic response.	Carbohydrates	97-109	insulin like growth factor binding protein 5	Homo sapiens	31-37
18602100-6	2008	The delivery of GST fused to HIV-Tat was competed by either IGFBP-3 or IGFBP-5-derived synthetic peptides.	Peptides	97-105	insulin like growth factor binding protein 5	Homo sapiens	71-78
17892529-4	2007	Immunohistochemistry performed on paraffin sections of the involuting mammary gland revealed IGFBP-5 positive staining of epithelial cells only outside the nucleus.	Paraffin	34-42	insulin like growth factor binding protein 5	Homo sapiens	93-100
17899320-5	2008	We analyse the interaction of IGFBP-5 (and IGFBP-3) with heparin and other biomolecules and describe experiments, which were designed to monitor multi-protein complex formation in this molecular axis.	Heparin	57-64	insulin like growth factor binding protein 5	Homo sapiens	30-37
17892529-5	2007	To evaluate the contribution of reuptake of extracellular IGFBP-5, T47D cells were incubated with Alexa Fluor 647-labeled IGFBP-5.	Alexa Fluor 647	98-113	insulin like growth factor binding protein 5	Homo sapiens	122-129
17892529-8	2007	The observation of nuclear uptake of IGFBP-5 was restricted to artificial conditions such as expression of non-secreted forms of IGFBP-5 or selective permeabilization of the plasma membrane by digitonin.	Digitonin	193-202	insulin like growth factor binding protein 5	Homo sapiens	37-44
17595320-0	2007	Insulin-like growth factor binding protein-5 interacts with the vitamin D receptor and modulates the vitamin D response in osteoblasts.	Vitamin D	64-73	insulin like growth factor binding protein 5	Homo sapiens	0-44
17804819-6	2007	In addition, treatment with IGFBP-5 protein or up-regulation of IGFBP-5 in young cells accelerates cellular senescence, as confirmed by cell proliferation and SA-beta-gal staining.	2-chloro-10-(4'(N-beta-hydroxyethyl)piperazinyl-1')acetylphenothiazine	159-161	insulin like growth factor binding protein 5	Homo sapiens	28-35
17804819-6	2007	In addition, treatment with IGFBP-5 protein or up-regulation of IGFBP-5 in young cells accelerates cellular senescence, as confirmed by cell proliferation and SA-beta-gal staining.	2-chloro-10-(4'(N-beta-hydroxyethyl)piperazinyl-1')acetylphenothiazine	159-161	insulin like growth factor binding protein 5	Homo sapiens	64-71
17804819-6	2007	In addition, treatment with IGFBP-5 protein or up-regulation of IGFBP-5 in young cells accelerates cellular senescence, as confirmed by cell proliferation and SA-beta-gal staining.	beta-D-galactose	162-170	insulin like growth factor binding protein 5	Homo sapiens	28-35
17804819-6	2007	In addition, treatment with IGFBP-5 protein or up-regulation of IGFBP-5 in young cells accelerates cellular senescence, as confirmed by cell proliferation and SA-beta-gal staining.	beta-D-galactose	162-170	insulin like growth factor binding protein 5	Homo sapiens	64-71
17823924-9	2007	IGFBP5 is most consistently increased and the increase in expression is reversed by testosterone administration.	Testosterone	84-96	insulin like growth factor binding protein 5	Homo sapiens	0-6
17595320-7	2007	Induction of osteocalcin promoter activity and alkaline phosphatase activity by 1,25(OH)2D3 were significantly enhanced when IGFBP-5 was down-regulated in U2-OS cells.	Calcitriol	80-91	insulin like growth factor binding protein 5	Homo sapiens	125-132
17033268-11	2006	In retinal and glomerular EC the IGFBP4/IGFBP5 ratio controls the response of these cells to IGF-I and high levels of glucose, in terms of cellular growth.	Glucose	118-125	insulin like growth factor binding protein 5	Homo sapiens	40-46
17496250-2	2007	Here we demonstrate that the analysis of tryptic peptides together with analysis of the full-length protein provided optimal characterization of insulin-like growth factor-binding protein-5 (IGFBP-5) phosphorylation and glycosylation.	Peptides	49-57	insulin like growth factor binding protein 5	Homo sapiens	145-189
17496250-2	2007	Here we demonstrate that the analysis of tryptic peptides together with analysis of the full-length protein provided optimal characterization of insulin-like growth factor-binding protein-5 (IGFBP-5) phosphorylation and glycosylation.	Peptides	49-57	insulin like growth factor binding protein 5	Homo sapiens	191-198
17496250-11	2007	IGFBP-5 was heterogeneously O-glycosylated mainly by sialylated core 1 type glycans.	Polysaccharides	76-83	insulin like growth factor binding protein 5	Homo sapiens	0-7
17496250-14	2007	Phosphorylation and O-glycosylation both affected IGFBP-5 binding to heparin but not insulin-like growth factor binding or ternary complex formation with the acid-labile subunit.	Heparin	69-76	insulin like growth factor binding protein 5	Homo sapiens	50-57
17496250-15	2007	The results reveal the first description of the in vivo phosphorylation of IGFBP-5 and its glycan composition.	Polysaccharides	91-97	insulin like growth factor binding protein 5	Homo sapiens	75-82
17332286-3	2007	RESULTS: Quantitative reverse transcription-PCR analysis showed that IGFBP3 and IGFBP5 were down-regulated and IGFBP4 was up-regulated by 17beta-estradiol (E(2)) in an estrogen receptor (ER)-positive ovarian cancer cell line.	Estradiol	138-154	insulin like growth factor binding protein 5	Homo sapiens	80-86
17332656-1	2007	BACKGROUND & OBJECTIVE: Insulin like growth factor binding proteins (IGFBPs) control the distribution, function and activity of insulin like growth factors (IGFs) in various cells, tissues and body fluids, thereby modulating their metabolic and mitogenic effects.	Adenosine Monophosphate	12-15	insulin like growth factor binding protein 5	Homo sapiens	73-79
16672690-6	2006	Anti-sense morpholino oligonucleotide inhibition of expression of LNalpha(4) substantially reduced expression of LN-8/9 (alpha(4)beta(1)gamma(1)/alpha(4)beta(2)gamma(1), 411/421) and prevented IGFBP-5-induced migration.	Morpholinos	11-37	insulin like growth factor binding protein 5	Homo sapiens	193-200
17242174-7	2007	The CACCC element has also been shown to be important for induction of the IGFBP5 promoter by retinoic acid (RA) and progesterone (Pg).	Tretinoin	94-107	insulin like growth factor binding protein 5	Homo sapiens	75-81
17242174-7	2007	The CACCC element has also been shown to be important for induction of the IGFBP5 promoter by retinoic acid (RA) and progesterone (Pg).	Tretinoin	109-111	insulin like growth factor binding protein 5	Homo sapiens	75-81
17242174-7	2007	The CACCC element has also been shown to be important for induction of the IGFBP5 promoter by retinoic acid (RA) and progesterone (Pg).	Progesterone	117-129	insulin like growth factor binding protein 5	Homo sapiens	75-81
17242174-7	2007	The CACCC element has also been shown to be important for induction of the IGFBP5 promoter by retinoic acid (RA) and progesterone (Pg).	Progesterone	131-133	insulin like growth factor binding protein 5	Homo sapiens	75-81
16554018-0	2006	Mannan-binding lectin-associated serine protease 3 cleaves synthetic peptides and insulin-like growth factor-binding protein 5.	Mannans	0-6	insulin like growth factor binding protein 5	Homo sapiens	82-126
16390864-10	2006	Hormone administration did not change IGFBP-4, whereas in men IGFBP-5 increased by 20% after GH (P < 0.05) and 56% after GH + testosterone (P = 0.0003).	Testosterone	129-141	insulin like growth factor binding protein 5	Homo sapiens	62-69
16282442-7	2006	G1 cell cycle block of MG-SPs may be explained by higher expression of cell cycle-negative regulatory genes such as transforming growth factor-beta2, insulin-like growth factor binding protein-5, P18(INK4C), and wingless-5a (Wnt-5a).	mg-sps	23-29	insulin like growth factor binding protein 5	Homo sapiens	150-194
16214131-7	2005	Simultaneous immunoneutralization of both IGFBP-3 and IGFBP-5 in TGF-beta1 or myostatin-treated PEMC cultures restores Long-R3-IGF-I-stimulated DNA synthesis rates to 90% of the levels observed in control cultures receiving no TGF-beta1 or myostatin treatment (P < 0.05).	pemc	96-100	insulin like growth factor binding protein 5	Homo sapiens	54-61
16311053-7	2006	Dexamethasone (Dex), an inhibitor of bone formation, decreased IGFBP-5 and FHL-2 and increased ADAM-9 in LSaOS cells (P < or = 0.05).	Dexamethasone	0-3	insulin like growth factor binding protein 5	Homo sapiens	63-70
16311053-10	2006	The BMP-7-induced increase in IGFBP-5 was reduced, but not eliminated, in the presence of Dex (P < or = 0.01), indicating that BMP-7 and Dex may regulate IGFBP-5 via different mechanisms.	Dexamethasone	90-93	insulin like growth factor binding protein 5	Homo sapiens	30-37
16311053-10	2006	The BMP-7-induced increase in IGFBP-5 was reduced, but not eliminated, in the presence of Dex (P < or = 0.01), indicating that BMP-7 and Dex may regulate IGFBP-5 via different mechanisms.	Dexamethasone	90-93	insulin like growth factor binding protein 5	Homo sapiens	157-164
16311053-10	2006	The BMP-7-induced increase in IGFBP-5 was reduced, but not eliminated, in the presence of Dex (P < or = 0.01), indicating that BMP-7 and Dex may regulate IGFBP-5 via different mechanisms.	Dexamethasone	140-143	insulin like growth factor binding protein 5	Homo sapiens	30-37
16311053-10	2006	The BMP-7-induced increase in IGFBP-5 was reduced, but not eliminated, in the presence of Dex (P < or = 0.01), indicating that BMP-7 and Dex may regulate IGFBP-5 via different mechanisms.	Dexamethasone	140-143	insulin like growth factor binding protein 5	Homo sapiens	157-164
16214131-3	2005	Furthermore, immunoneutralization of endogenous IGFBP-3 and IGFBP-5 in the PEMC culture medium results in increased DNA synthesis rate suggesting that endogenous IGFBP-3 and IGFBP-5 suppress PEMC proliferation.	pemc	75-79	insulin like growth factor binding protein 5	Homo sapiens	60-67
16214131-3	2005	Furthermore, immunoneutralization of endogenous IGFBP-3 and IGFBP-5 in the PEMC culture medium results in increased DNA synthesis rate suggesting that endogenous IGFBP-3 and IGFBP-5 suppress PEMC proliferation.	pemc	75-79	insulin like growth factor binding protein 5	Homo sapiens	174-181
16311053-7	2006	Dexamethasone (Dex), an inhibitor of bone formation, decreased IGFBP-5 and FHL-2 and increased ADAM-9 in LSaOS cells (P < or = 0.05).	Dexamethasone	0-13	insulin like growth factor binding protein 5	Homo sapiens	63-70
16214131-9	2005	These findings strongly suggest that IGFBP-3 and IGFBP-5 affect processes downstream from receptor-mediated Smad phosphorylation that facilitate the ability of TGF-beta and myostatin to suppress proliferation of PEMC.	pemc	212-216	insulin like growth factor binding protein 5	Homo sapiens	49-56
16214131-3	2005	Furthermore, immunoneutralization of endogenous IGFBP-3 and IGFBP-5 in the PEMC culture medium results in increased DNA synthesis rate suggesting that endogenous IGFBP-3 and IGFBP-5 suppress PEMC proliferation.	pemc	191-195	insulin like growth factor binding protein 5	Homo sapiens	60-67
16411814-10	2005	However, coating the scaffolds with complexes composed of VN + IGF-I or VN + IGFBP-5 + IGF-I enhanced cell attachment on PGA.	Polyglycolic Acid	121-124	insulin like growth factor binding protein 5	Homo sapiens	77-84
16214131-3	2005	Furthermore, immunoneutralization of endogenous IGFBP-3 and IGFBP-5 in the PEMC culture medium results in increased DNA synthesis rate suggesting that endogenous IGFBP-3 and IGFBP-5 suppress PEMC proliferation.	pemc	191-195	insulin like growth factor binding protein 5	Homo sapiens	174-181
15650232-7	2004	RA-induced differentiation causes a sharp increase of IGFBP-5.	Tretinoin	0-2	insulin like growth factor binding protein 5	Homo sapiens	54-61
15777798-3	2005	We found that IGFBP-5 expression increased during retinoic acid (RA)-mediated differentiation of NB cells.	Tretinoin	50-63	insulin like growth factor binding protein 5	Homo sapiens	14-21
15777798-3	2005	We found that IGFBP-5 expression increased during retinoic acid (RA)-mediated differentiation of NB cells.	Tretinoin	65-67	insulin like growth factor binding protein 5	Homo sapiens	14-21
15777798-5	2005	We defined the shortest region of the human IGFBP-5 promoter (from nucleotide -83 to +53) which is sensitive to RA.	Tretinoin	112-114	insulin like growth factor binding protein 5	Homo sapiens	44-51
15534875-9	2005	Mutation of the active site serine resulted in a major reduction in IGFBP-5 cleavage.	Serine	28-34	insulin like growth factor binding protein 5	Homo sapiens	68-75
15534875-10	2005	The protease binds to heparin and its ability to degrade IGFBP-5 is blocked in the presence of heparin.	Heparin	22-29	insulin like growth factor binding protein 5	Homo sapiens	57-64
15534875-10	2005	The protease binds to heparin and its ability to degrade IGFBP-5 is blocked in the presence of heparin.	Heparin	95-102	insulin like growth factor binding protein 5	Homo sapiens	57-64
15817840-9	2005	The anti-rpIGFBP-5 IgY produced against rpIGFBP-5 specifically recognized native porcine IGFBP-5 in PEMC media that also contained porcine IGFBP-2, -3, and -4.	pemc	100-104	insulin like growth factor binding protein 5	Homo sapiens	11-18
15650232-9	2004	We show that the effect of RA on the IGFBP-5 promoter is exerted, at least in part, through a proximal 5"-CACCC-3" tandem repeat (-147 bp to -137 bp from the transcription start site) that has previously been described as a cis-acting element involved in the progesterone-mediated response in osteoblasts.	Tretinoin	27-29	insulin like growth factor binding protein 5	Homo sapiens	37-44
15650232-9	2004	We show that the effect of RA on the IGFBP-5 promoter is exerted, at least in part, through a proximal 5"-CACCC-3" tandem repeat (-147 bp to -137 bp from the transcription start site) that has previously been described as a cis-acting element involved in the progesterone-mediated response in osteoblasts.	Progesterone	259-271	insulin like growth factor binding protein 5	Homo sapiens	37-44
12376561-8	2002	On plastic, neither IGFBP-3 nor -5 alone affected cell viability; although ceramide-induced apoptosis was enhanced by IGFBP-3 but reduced by IGFBP-5.	Ceramides	75-83	insulin like growth factor binding protein 5	Homo sapiens	141-148
15262980-9	2004	Individual substitution of conserved LNR residues predicted to participate in calcium coordination caused elimination (D341A, D356A, D389A, D1484A, D1499A, and D1502A) or a significant reduction (D359A and E392A) of IGFBP-4 proteolysis, whereas IGFBP-5 proteolysis was unaffected.	Calcium	78-85	insulin like growth factor binding protein 5	Homo sapiens	245-252
15155755-5	2004	Knock-down of IGFBP-5 resulted in a significant increase in the number of transferase-mediated dUTP nick end labeling-positive cells and a decrease in a bone differentiation parameter (alkaline phosphatase activity) but had little effect on basal or insulin-like growth factor I-induced proliferation.	deoxyuridine triphosphate	95-99	insulin like growth factor binding protein 5	Homo sapiens	14-21
14515014-5	2003	Zn2+, Cd2+, and Au3+, but not La3+, decreased total binding and the affinity for [125I]IGF-II association with IGFBP-3 and IGFBP-5.	Zinc	0-4	insulin like growth factor binding protein 5	Homo sapiens	123-130
14515014-9	2003	Together with the current work, these findings imply that Zn2+ acts in vivo to prevent secreted IGF-II from binding to IGFBP-3 and IGFBP- 5, thus maintaining IGF-II in an "active state," i.e., readily available for IGF-1R association.	Zinc	58-62	insulin like growth factor binding protein 5	Homo sapiens	131-139
12484779-2	2002	Therefore, elucidation of the identity of IGF binding protein-5 (BP-5) protease produced by osteoblasts is important for our understanding of the molecular pathways that control the action of BP-5.	bp-5	65-69	insulin like growth factor binding protein 5	Homo sapiens	42-63
14645245-4	2004	The complex formation of IGFBP-5 and FN was established by glutathione S-transferase pull-down, solution, and solid phase binding assays using glutathione S-transferase-IGFBP-5 and native IGFBP-5 in vitro and by co-immunoprecipitation in vivo.	Glutathione	59-70	insulin like growth factor binding protein 5	Homo sapiens	25-32
14645245-4	2004	The complex formation of IGFBP-5 and FN was established by glutathione S-transferase pull-down, solution, and solid phase binding assays using glutathione S-transferase-IGFBP-5 and native IGFBP-5 in vitro and by co-immunoprecipitation in vivo.	Glutathione	143-154	insulin like growth factor binding protein 5	Homo sapiens	25-32
12917428-10	2003	This effect of IGFBP-5 was inhibited by soluble heparin and by treating cells with heparinase.	Heparin	48-55	insulin like growth factor binding protein 5	Homo sapiens	15-22
12777377-4	2003	IGFBP-5 expression resulted in a G2/M cell cycle arrest and the induction of apoptosis in both cell lines, an effect that was abrogated in the presence of the broad-spectrum caspase inhibitor, z-VAD-fmk.	benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone	193-202	insulin like growth factor binding protein 5	Homo sapiens	0-7
12375264-8	2002	Administration of a green tea compound with anti-cancer properties, (-)-epigallocatechin 3-gallate, at a concentration of 5-20 micro g/ml also up-regulated IGFBP-5 expression in NHOKs in a dose-dependent manner.	epigallocatechin gallate	68-98	insulin like growth factor binding protein 5	Homo sapiens	156-163
12176674-10	2002	Treatment with DXM (100 nM) resulted in a 2-fold increase in mRNA levels of both IGFBP-5 and the type I IGF receptor, whereas IGFBP-2 mRNA levels decreased by 55%, in concert with the decrease in protein level observed under IGF-I-supplemented culture conditions.	Dexamethasone	15-18	insulin like growth factor binding protein 5	Homo sapiens	81-88
11923300-10	2002	IGFBP-5 caused a concentration-dependent increase in [(3)H]thymidine incorporation and an increase in IGF-I secretion that occurred independently of IGF-I and the IGF-I receptor tyrosine kinase.	Thymidine	59-68	insulin like growth factor binding protein 5	Homo sapiens	0-7
12074575-1	2002	We have demonstrated previously that IGFBP-5 alone had no effect on cell death but modulated ceramide-induced apoptosis in Hs578T IGF non-responsive cells.	Ceramides	93-101	insulin like growth factor binding protein 5	Homo sapiens	37-44
12074575-6	2002	In summary, all forms of IGFBP-5 modulated ceramide-induced apoptosis in Hs578T cells.	Ceramides	43-51	insulin like growth factor binding protein 5	Homo sapiens	25-32
11923300-12	2002	IGFBP-5-stimulated [(3)H]thymidine incorporation and IGF-I secretion were partly inhibited by SB203580 or U1026 and abolished by the combination of the two inhibitors or by expression of Ras(S17N).	u1026	106-111	insulin like growth factor binding protein 5	Homo sapiens	0-7
11923300-11	2002	IGFBP-5-induced phosphorylation of p38 MAP kinase, which was abolished by SB203580, or expression of a dominant negative Ras mutant, Ras(S17N), and phosphorylation of Erk1/2, which was abolished by a Raf1 kinase inhibitor, U1026, or expression of Ras(S17N).	SB 203580	74-82	insulin like growth factor binding protein 5	Homo sapiens	0-7
11923300-12	2002	IGFBP-5-stimulated [(3)H]thymidine incorporation and IGF-I secretion were partly inhibited by SB203580 or U1026 and abolished by the combination of the two inhibitors or by expression of Ras(S17N).	Thymidine	25-34	insulin like growth factor binding protein 5	Homo sapiens	0-7
11923300-12	2002	IGFBP-5-stimulated [(3)H]thymidine incorporation and IGF-I secretion were partly inhibited by SB203580 or U1026 and abolished by the combination of the two inhibitors or by expression of Ras(S17N).	SB 203580	94-102	insulin like growth factor binding protein 5	Homo sapiens	0-7
10601276-8	1999	When LY294002 and wortmannin, two specific inhibitors of PI 3-kinase, were added with Des(1-3)IGF-I, the IGF-I-regulated IGFBP-5 expression was negated.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	5-13	insulin like growth factor binding protein 5	Homo sapiens	121-128
11835403-1	2002	We have demonstrated previously that IGFBP-5 can confer survival against apoptosis induced by ceramide, C2, or a small synthetic arginine-glycine-aspartic acid (RGD)-containing peptide in a direct manner.	Ceramides	94-102	insulin like growth factor binding protein 5	Homo sapiens	37-44
11835403-1	2002	We have demonstrated previously that IGFBP-5 can confer survival against apoptosis induced by ceramide, C2, or a small synthetic arginine-glycine-aspartic acid (RGD)-containing peptide in a direct manner.	A(2)C	104-106	insulin like growth factor binding protein 5	Homo sapiens	37-44
11835403-1	2002	We have demonstrated previously that IGFBP-5 can confer survival against apoptosis induced by ceramide, C2, or a small synthetic arginine-glycine-aspartic acid (RGD)-containing peptide in a direct manner.	arginyl-glycyl-aspartic acid	129-159	insulin like growth factor binding protein 5	Homo sapiens	37-44
11835403-12	2002	These data suggest that IGFBP-5 promotes the attachment and survival of Hs578T cells by modulating the balance between ceramide and opposing survival signals.	Ceramides	119-127	insulin like growth factor binding protein 5	Homo sapiens	24-31
11522292-4	2001	Cleavage occurs at one site, between Ser-143 and Lys-144 of IGFBP-5.	Serine	37-40	insulin like growth factor binding protein 5	Homo sapiens	60-67
11522292-4	2001	Cleavage occurs at one site, between Ser-143 and Lys-144 of IGFBP-5.	Lysine	49-52	insulin like growth factor binding protein 5	Homo sapiens	60-67
11179972-0	2001	NMR 15N relaxation of the insulin-like growth factor (IGF)-binding domain of IGF binding protein-5 (IGFBP-5) determined free in solution and in complex with IGF-II.	15n	4-7	insulin like growth factor binding protein 5	Homo sapiens	77-98
11179972-0	2001	NMR 15N relaxation of the insulin-like growth factor (IGF)-binding domain of IGF binding protein-5 (IGFBP-5) determined free in solution and in complex with IGF-II.	15n	4-7	insulin like growth factor binding protein 5	Homo sapiens	100-107
11179972-1	2001	15N NMR relaxation rates of mini-IGFBP-5, an N-terminal insulin-like growth factor binding domain of the insulin-like growth factor binding protein 5 (IGFBP-5), were analysed at three field strengths using the Lipari-Szabo procedure (see below) and reduced spectral density methods.	15n	0-3	insulin like growth factor binding protein 5	Homo sapiens	33-40
11179972-1	2001	15N NMR relaxation rates of mini-IGFBP-5, an N-terminal insulin-like growth factor binding domain of the insulin-like growth factor binding protein 5 (IGFBP-5), were analysed at three field strengths using the Lipari-Szabo procedure (see below) and reduced spectral density methods.	15n	0-3	insulin like growth factor binding protein 5	Homo sapiens	105-149
11179972-1	2001	15N NMR relaxation rates of mini-IGFBP-5, an N-terminal insulin-like growth factor binding domain of the insulin-like growth factor binding protein 5 (IGFBP-5), were analysed at three field strengths using the Lipari-Szabo procedure (see below) and reduced spectral density methods.	15n	0-3	insulin like growth factor binding protein 5	Homo sapiens	151-158
10884189-10	2000	Serum free thyroxine showed a positive correlation with serum levels of IGF-I (r = 0.73, p < 0.05), IGFBP-3 (r = 0.59, p < 0.05), and IGFBP-4 (r = 0.67, p < 0.05) but not IGFBP-5.	Thyroxine	11-20	insulin like growth factor binding protein 5	Homo sapiens	180-187
10698186-6	2000	In contrast, both heparin and heparan sulfate significantly inhibited the OPN-IGFBP-5 interaction and chondroitin sulfate A, B, and C had no effect.	Heparin	18-25	insulin like growth factor binding protein 5	Homo sapiens	78-85
10698186-6	2000	In contrast, both heparin and heparan sulfate significantly inhibited the OPN-IGFBP-5 interaction and chondroitin sulfate A, B, and C had no effect.	Heparitin Sulfate	30-45	insulin like growth factor binding protein 5	Homo sapiens	78-85
11745462-14	2001	These results suggest that the loss of IGFBP-5 and possibly IGF-R2, both of which can sequester IGF-I from IGF-R1, permits unhindered proliferation of the premalignant EVT in an IGF-I rich environment of the fetal-maternal interface.	EVT	168-171	insulin like growth factor binding protein 5	Homo sapiens	39-46
11264294-6	2001	We showed that PAPP-A2 specifically cleaved IGFBP-5 at one site, between Ser-143 and Lys-144.	Serine	73-76	insulin like growth factor binding protein 5	Homo sapiens	44-51
11264294-6	2001	We showed that PAPP-A2 specifically cleaved IGFBP-5 at one site, between Ser-143 and Lys-144.	Lysine	85-88	insulin like growth factor binding protein 5	Homo sapiens	44-51
11316783-0	2001	Mutagenesis of basic amino acids in the carboxyl-terminal region of insulin-like growth factor binding protein-5 affects acid-labile subunit binding.	Amino Acids, Basic	15-32	insulin like growth factor binding protein 5	Homo sapiens	68-112
10792618-10	2000	Staurosporin inhibits cell migration and Cdc42GAP aggregation only when added within the first hour, suggesting that it inhibits the stimulatory effect of IGFBP-5201-218 by blocking the IGFBP-5 receptor serine/threonine kinase activity.	Staurosporine	0-12	insulin like growth factor binding protein 5	Homo sapiens	155-162
10601276-8	1999	When LY294002 and wortmannin, two specific inhibitors of PI 3-kinase, were added with Des(1-3)IGF-I, the IGF-I-regulated IGFBP-5 expression was negated.	Wortmannin	18-28	insulin like growth factor binding protein 5	Homo sapiens	121-128
10601276-9	1999	The addition of rapamycin, which inhibits IGF-I-induced p70(s6k) activation, significantly inhibited IGF-I-regulated IGFBP-5 gene expression.	Sirolimus	16-25	insulin like growth factor binding protein 5	Homo sapiens	117-124
10499519-8	1999	Both PMA (1 microM) and GF109203X (20 microM) nearly completely suppressed the total PKC activity after a 30-min incubation (> 90%), and this inhibition lasted for at least 24 h. Down-regulation or inhibition of PKC activity abolished the IGF-I-induced DNA synthesis, migration and IGFBP-5 gene expression.	bisindolylmaleimide I	24-33	insulin like growth factor binding protein 5	Homo sapiens	285-292
10499512-2	1999	PGE2 rapidly increases IGFBP-5 expression by osteoblasts through cAMP-dependent processes.	Dinoprostone	0-4	insulin like growth factor binding protein 5	Homo sapiens	23-30
10499501-6	1999	The phosphatidylinositol-3 kinase inhibitor (LY294002), but not the mitogen-activated protein kinase kinase inhibitor (PD98059), blocks IGF-I enhancement of IGFBP-5 gene and protein expression.	2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one	45-53	insulin like growth factor binding protein 5	Homo sapiens	157-164
10499512-2	1999	PGE2 rapidly increases IGFBP-5 expression by osteoblasts through cAMP-dependent processes.	Cyclic AMP	65-69	insulin like growth factor binding protein 5	Homo sapiens	23-30
10499519-9	1999	In contrast, the IGFBP-5 expression induced by forskolin was unaffected by PKC down-regulation or inhibition, suggesting that PKC activation is required for the IGF-regulated but not the cAMP-regulated events.	Colforsin	47-56	insulin like growth factor binding protein 5	Homo sapiens	17-24
10499512-3	1999	A minimal DNA sequence required for basal and PGE2-stimulated IGFBP-5 promoter activity spans -69 to -35 bp.	Dinoprostone	46-50	insulin like growth factor binding protein 5	Homo sapiens	62-69
10499512-13	1999	These results identify several elements as integral binding sequences for both basal and PGE2-stimulated IGFBP-5 promoter activity.	Dinoprostone	89-93	insulin like growth factor binding protein 5	Homo sapiens	105-112
10499512-14	1999	They further reveal that multiple sequences within this cluster form a basic transcription unit where nuclear factors can accumulate in a protein synthesis-dependent way and enhance IGFBP-5 expression by osteoblasts in response to PGE2.	Dinoprostone	231-235	insulin like growth factor binding protein 5	Homo sapiens	182-189
10517168-3	1999	Hence, we reasoned that the inhibition of tamoxifen-resistant cell growth by ICI 182,780 might have been due to increased expression of insulin-like growth factor binding proteins (IGFBPs).	Tamoxifen	42-51	insulin like growth factor binding protein 5	Homo sapiens	181-187
10473602-2	1999	Progesterone (PG) increased IGFBP-5 expression in normal human osteoblasts and increased IGFBP-5 transcription in U2 human osteosarcoma cells.	Progesterone	0-12	insulin like growth factor binding protein 5	Homo sapiens	28-35
10473602-2	1999	Progesterone (PG) increased IGFBP-5 expression in normal human osteoblasts and increased IGFBP-5 transcription in U2 human osteosarcoma cells.	Progesterone	0-12	insulin like growth factor binding protein 5	Homo sapiens	89-96
10473602-2	1999	Progesterone (PG) increased IGFBP-5 expression in normal human osteoblasts and increased IGFBP-5 transcription in U2 human osteosarcoma cells.	Progesterone	14-16	insulin like growth factor binding protein 5	Homo sapiens	28-35
10473602-2	1999	Progesterone (PG) increased IGFBP-5 expression in normal human osteoblasts and increased IGFBP-5 transcription in U2 human osteosarcoma cells.	Progesterone	14-16	insulin like growth factor binding protein 5	Homo sapiens	89-96
10473602-5	1999	Analysis of 5" deletion constructs indicates that PG transactivation of IGFBP-5 promoter activity does not require the PG response element half-sites but does require the region -162 to -124 containing two tandem CACCC box sequences.	Progesterone	50-52	insulin like growth factor binding protein 5	Homo sapiens	72-79
10473602-8	1999	Using a luciferase reporter construct containing base pairs -252 to +24 of the IGFBP-5 promoter, we found that both PR(A) and PR(B) isoforms mediated PG stimulation of promoter activity.	Progesterone	150-152	insulin like growth factor binding protein 5	Homo sapiens	79-86
10473602-9	1999	These results suggest that PG may stimulate IGFBP-5 gene transcription via a novel mechanism involving PR and CACCC-binding factors.	Progesterone	27-29	insulin like growth factor binding protein 5	Homo sapiens	44-51
10427145-8	1999	Furthermore, we demonstrate that an antisense IGFBP-5 oligodeoxynucleotide attenuates EB1089-induced inhibition of IGF-I-stimulated tyrosine phosphorylation of IRS-1 and EB1089-induced IGFBP-5 accumulation.	Oligodeoxyribonucleotides	54-74	insulin like growth factor binding protein 5	Homo sapiens	46-53
10427145-8	1999	Furthermore, we demonstrate that an antisense IGFBP-5 oligodeoxynucleotide attenuates EB1089-induced inhibition of IGF-I-stimulated tyrosine phosphorylation of IRS-1 and EB1089-induced IGFBP-5 accumulation.	Oligodeoxyribonucleotides	54-74	insulin like growth factor binding protein 5	Homo sapiens	185-192
10427145-8	1999	Furthermore, we demonstrate that an antisense IGFBP-5 oligodeoxynucleotide attenuates EB1089-induced inhibition of IGF-I-stimulated tyrosine phosphorylation of IRS-1 and EB1089-induced IGFBP-5 accumulation.	Tyrosine	132-140	insulin like growth factor binding protein 5	Homo sapiens	46-53
10517168-4	1999	We observed the up-regulation of non-insulin-suppressible IGF-I binding in both the tamoxifen-sensitive MCF 7/5-21 cell line (1.5-fold) and the tamoxifen-resistant MCF 7/5-23 cell line (2.5-fold) after 5 days of treatment with ICI 182,780 (10(-7) M) in serum-free medium, suggesting a role for cell-associated IGFBPs.	Tamoxifen	84-93	insulin like growth factor binding protein 5	Homo sapiens	310-316
10329650-6	1999	The next two linkages are Cys7-Cys9 and Cys8-Cys10, which are analogous to those previously determined for IGFBP-3 and IGFBP-5.	CYS7	26-30	insulin like growth factor binding protein 5	Homo sapiens	119-126
10329650-9	1999	Analogous with IGFBP-3, IGFBP-5, and IGFBP-6, Cys9-Cys11 and Cys10-Cys12 of IGFBP-1 are also disulfide-linked.	Disulfides	93-102	insulin like growth factor binding protein 5	Homo sapiens	24-31
9831081-12	1998	IGFBP-5 and IGFBP-6 mRNA levels were decreased by Dex in a time-dependent fashion.	Dexamethasone	50-53	insulin like growth factor binding protein 5	Homo sapiens	0-7
9927280-8	1999	This cell-associated IGFBP was deduced to be IGFBP-5 based on its molecular size, detection of IGFBP-5 messenger RNA only in slow growing clones, and competition of its binding by heparin.	Heparin	180-187	insulin like growth factor binding protein 5	Homo sapiens	45-52
10218991-7	1999	IGFBP-5 protein in tumor extracts bound 125I-labeled IGF-I in ligand blot assays and the amounts of IGFBP-5 measured by immunoblotting paralleled the levels of IGFBP-5 mRNA.	Iodine-125	40-44	insulin like growth factor binding protein 5	Homo sapiens	0-7
10218991-8	1999	Androgen-induced expression of IGFBP-5 was at a maximum level within 24 h after testosterone replacement, whereas the major increase in cell proliferation as measured by Ki-67 immunostaining occurred between 24-48 h. This time course suggested IGFBP-5 may be a mediator of androgen-induced growth of CWR22.	Testosterone	80-92	insulin like growth factor binding protein 5	Homo sapiens	31-38
9883900-3	1998	Identification of IGFBP-5 peptides in the fractions of our peptide bank generated from hemofiltrate was performed by their immunoreactivity and their capacity to bind IGF-I.	hemofiltrate	87-99	insulin like growth factor binding protein 5	Homo sapiens	18-25
9883900-7	1998	In addition, a smaller fragment with Mr 2722 of the central IGFBP-5 region was purified and showed the sequence HTRISELKAEAVKKDRRKKLTQS (residues 121-143) indicating plasma proteolysis of IGFBP-5 C-terminal to amino acids Lys-120, Ser-143, Lys-144, and Arg-188.	Lysine	222-225	insulin like growth factor binding protein 5	Homo sapiens	60-67
9883900-7	1998	In addition, a smaller fragment with Mr 2722 of the central IGFBP-5 region was purified and showed the sequence HTRISELKAEAVKKDRRKKLTQS (residues 121-143) indicating plasma proteolysis of IGFBP-5 C-terminal to amino acids Lys-120, Ser-143, Lys-144, and Arg-188.	Lysine	222-225	insulin like growth factor binding protein 5	Homo sapiens	188-195
9883900-7	1998	In addition, a smaller fragment with Mr 2722 of the central IGFBP-5 region was purified and showed the sequence HTRISELKAEAVKKDRRKKLTQS (residues 121-143) indicating plasma proteolysis of IGFBP-5 C-terminal to amino acids Lys-120, Ser-143, Lys-144, and Arg-188.	Serine	231-234	insulin like growth factor binding protein 5	Homo sapiens	60-67
9883900-7	1998	In addition, a smaller fragment with Mr 2722 of the central IGFBP-5 region was purified and showed the sequence HTRISELKAEAVKKDRRKKLTQS (residues 121-143) indicating plasma proteolysis of IGFBP-5 C-terminal to amino acids Lys-120, Ser-143, Lys-144, and Arg-188.	Serine	231-234	insulin like growth factor binding protein 5	Homo sapiens	188-195
9883900-7	1998	In addition, a smaller fragment with Mr 2722 of the central IGFBP-5 region was purified and showed the sequence HTRISELKAEAVKKDRRKKLTQS (residues 121-143) indicating plasma proteolysis of IGFBP-5 C-terminal to amino acids Lys-120, Ser-143, Lys-144, and Arg-188.	Lysine	240-243	insulin like growth factor binding protein 5	Homo sapiens	60-67
9883900-7	1998	In addition, a smaller fragment with Mr 2722 of the central IGFBP-5 region was purified and showed the sequence HTRISELKAEAVKKDRRKKLTQS (residues 121-143) indicating plasma proteolysis of IGFBP-5 C-terminal to amino acids Lys-120, Ser-143, Lys-144, and Arg-188.	Lysine	240-243	insulin like growth factor binding protein 5	Homo sapiens	188-195
9883900-7	1998	In addition, a smaller fragment with Mr 2722 of the central IGFBP-5 region was purified and showed the sequence HTRISELKAEAVKKDRRKKLTQS (residues 121-143) indicating plasma proteolysis of IGFBP-5 C-terminal to amino acids Lys-120, Ser-143, Lys-144, and Arg-188.	Arginine	253-256	insulin like growth factor binding protein 5	Homo sapiens	60-67
9883900-7	1998	In addition, a smaller fragment with Mr 2722 of the central IGFBP-5 region was purified and showed the sequence HTRISELKAEAVKKDRRKKLTQS (residues 121-143) indicating plasma proteolysis of IGFBP-5 C-terminal to amino acids Lys-120, Ser-143, Lys-144, and Arg-188.	Arginine	253-256	insulin like growth factor binding protein 5	Homo sapiens	188-195
9831081-13	1998	IGFBP-5 protein level was also decreased 1-4 days after Dex treatment.	Dexamethasone	56-59	insulin like growth factor binding protein 5	Homo sapiens	0-7
9786878-10	1998	The glycosaminoglycans heparin and heparan sulfate bind to IGFBP-5 through its basic carboxyl-terminal domain.	Glycosaminoglycans	4-22	insulin like growth factor binding protein 5	Homo sapiens	59-66
9838220-4	1998	Serine protease inhibitors aprotinin and heparin effectively inhibited the breakdown of IGFBP-5.	Heparin	41-48	insulin like growth factor binding protein 5	Homo sapiens	88-95
9786878-10	1998	The glycosaminoglycans heparin and heparan sulfate bind to IGFBP-5 through its basic carboxyl-terminal domain.	Heparin	23-30	insulin like growth factor binding protein 5	Homo sapiens	59-66
9786878-10	1998	The glycosaminoglycans heparin and heparan sulfate bind to IGFBP-5 through its basic carboxyl-terminal domain.	Heparitin Sulfate	35-50	insulin like growth factor binding protein 5	Homo sapiens	59-66
9786878-11	1998	At high concentrations, these glycosaminoglycans inhibited ALS binding to binary complexed IGF-BP-5.	Glycosaminoglycans	30-48	insulin like growth factor binding protein 5	Homo sapiens	91-99
9642243-3	1998	Previously, we have reported that porcine VSMCs synthesize and secrete IGF-I and several forms of IGFBPs, including IGFBP-2, IGFBP-4, and IGFBP-5.	vsmcs	42-47	insulin like growth factor binding protein 5	Homo sapiens	138-145
9725901-12	1998	The findings suggest that specific basic amino acids at positions 207 and 214 mediate the binding of IGFBP-5 to pSMC/ECM.	Amino Acids, Basic	35-52	insulin like growth factor binding protein 5	Homo sapiens	101-108
9725901-12	1998	The findings suggest that specific basic amino acids at positions 207 and 214 mediate the binding of IGFBP-5 to pSMC/ECM.	psmc	112-116	insulin like growth factor binding protein 5	Homo sapiens	101-108
9642243-10	1998	Since treatment of VSMC with exogenous IGF-I increased IGFBP-5 mRNA levels, we neutralized the effect of endogenously secreted IGF-I with an anti-IGF-I antibody to determine if it would alter IGFBP-5 mRNA abundance.	vsmc	19-23	insulin like growth factor binding protein 5	Homo sapiens	55-62
9564845-8	1998	Furthermore, IGFBP-5 underwent a time-dependent limited proteolysis when incubated with OAC-conditioned medium, degrading into 22- and 16-kDa fragments.	SDZ 33-243	88-91	insulin like growth factor binding protein 5	Homo sapiens	13-20
9610754-10	1998	The percentage increase of serum IGFBP-5 after GH therapy showed a positive correlation with the percentage increase of total alkaline phosphate activity (r = 0.347 p < 0.05).	alkaline phosphate	126-144	insulin like growth factor binding protein 5	Homo sapiens	33-40
9564845-16	1998	Our results demonstrate that IGF-I and IL-1alpha synergistically increase the level of IGFBP-5 in OAC by inhibiting the proteolysis and stimulating the expression of IGFBP-5, respectively.	SDZ 33-243	98-101	insulin like growth factor binding protein 5	Homo sapiens	87-94
9366575-3	1997	IGFBP-5 is synthesized by pSMC and binds to the extracellular matrix.	psmc	26-30	insulin like growth factor binding protein 5	Homo sapiens	0-7
9528953-7	1998	[35S]Methionine labeling followed by immunoprecipitation confirmed that IGFBP-5 that was constitutively synthesized by pSMC cultures was also degraded by thrombin into 24-, 23-, and 20-kDa fragments.	Sulfur-35	1-4	insulin like growth factor binding protein 5	Homo sapiens	72-79
9528953-7	1998	[35S]Methionine labeling followed by immunoprecipitation confirmed that IGFBP-5 that was constitutively synthesized by pSMC cultures was also degraded by thrombin into 24-, 23-, and 20-kDa fragments.	Methionine	5-15	insulin like growth factor binding protein 5	Homo sapiens	72-79
9528953-7	1998	[35S]Methionine labeling followed by immunoprecipitation confirmed that IGFBP-5 that was constitutively synthesized by pSMC cultures was also degraded by thrombin into 24-, 23-, and 20-kDa fragments.	psmc	119-123	insulin like growth factor binding protein 5	Homo sapiens	72-79
9398631-5	1997	Under these conditions IGFBP-3 and IGFBP-5, but not the other IGFBPs, formed high molecular weight disulfide-linked multimers.	Disulfides	99-108	insulin like growth factor binding protein 5	Homo sapiens	35-42
9366575-9	1997	This mutant IGFBP-5 remained intact even after 24 h of incubation and it inhibited several IGF-I actions when added to pSMC culture medium.	psmc	119-123	insulin like growth factor binding protein 5	Homo sapiens	12-19
9366575-10	1997	The mutant IGFBP-5 (500 ng/ml) decreased IGF-I stimulated cellular DNA synthesis by 84%, protein synthesis by 77%, and it inhibited IGF-I stimulated migration of pSMC by 77%.	psmc	162-166	insulin like growth factor binding protein 5	Homo sapiens	11-18
9366575-16	1997	In conclusion, the accumulation of protease-resistant IGFBP-5 in the medium was inhibitory to IGF-I actions on pSMC.	psmc	111-115	insulin like growth factor binding protein 5	Homo sapiens	54-61
9130463-11	1997	Both cAMP and Matrigel matrix treatment enhanced IGFBP-5 protein expression and cAMP increased IGFBP-5 gene expression five fold.	Cyclic AMP	5-9	insulin like growth factor binding protein 5	Homo sapiens	49-56
9202242-2	1997	The ECM-IGFBP-5 interaction is mediated in part by binding to heparan sulfate containing proteoglycans.	Heparitin Sulfate	62-77	insulin like growth factor binding protein 5	Homo sapiens	8-15
9202242-12	1997	Heparin and heparan sulfate inhibited the IGFBP-5/PAI-1 interaction; however, several other glycosaminoglycans had no effect.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	42-49
9202242-12	1997	Heparin and heparan sulfate inhibited the IGFBP-5/PAI-1 interaction; however, several other glycosaminoglycans had no effect.	Heparitin Sulfate	12-27	insulin like growth factor binding protein 5	Homo sapiens	42-49
9368678-7	1997	However, in contrast to TGF-beta 2, high concentrations of RA (1 microM) negatively regulated IGFBP-5 expression, with IGFBP-5 mRNA levels downregulated to 20% of that of the control, and protein levels were decreased by 50%.	Tretinoin	59-61	insulin like growth factor binding protein 5	Homo sapiens	94-101
9374687-1	1997	Using the major bone insulin-like growth factor-binding protein (IGFBP) IGFBP-5, we took a mechanistic approach in evaluating the role of the heparin-binding domain of IGFBP-5 in regulating plasmin (Pm) proteolysis of IGFBP-5.	Heparin	142-149	insulin like growth factor binding protein 5	Homo sapiens	168-175
9374687-1	1997	Using the major bone insulin-like growth factor-binding protein (IGFBP) IGFBP-5, we took a mechanistic approach in evaluating the role of the heparin-binding domain of IGFBP-5 in regulating plasmin (Pm) proteolysis of IGFBP-5.	Heparin	142-149	insulin like growth factor binding protein 5	Homo sapiens	168-175
9374687-2	1997	Using synthetic IGFBP-5 peptide fragments, we determined that the heparin-binding domain, IGFBP-5-(208-218), inhibits Pm proteolysis of intact IGFBP-5.	Heparin	66-73	insulin like growth factor binding protein 5	Homo sapiens	16-23
9374687-2	1997	Using synthetic IGFBP-5 peptide fragments, we determined that the heparin-binding domain, IGFBP-5-(208-218), inhibits Pm proteolysis of intact IGFBP-5.	Heparin	66-73	insulin like growth factor binding protein 5	Homo sapiens	90-97
9374687-2	1997	Using synthetic IGFBP-5 peptide fragments, we determined that the heparin-binding domain, IGFBP-5-(208-218), inhibits Pm proteolysis of intact IGFBP-5.	Heparin	66-73	insulin like growth factor binding protein 5	Homo sapiens	90-97
9374687-6	1997	These data indicate that the heparin-binding domain contains the serine protease (Pg-to-Pm) binding site region of IGFBP-5, and that this region, which is presumed to represent a Pm-induced proteolytic product of IGFBP-5, is capable of regulating Pm action.	Heparin	29-36	insulin like growth factor binding protein 5	Homo sapiens	115-122
9374687-6	1997	These data indicate that the heparin-binding domain contains the serine protease (Pg-to-Pm) binding site region of IGFBP-5, and that this region, which is presumed to represent a Pm-induced proteolytic product of IGFBP-5, is capable of regulating Pm action.	Heparin	29-36	insulin like growth factor binding protein 5	Homo sapiens	213-220
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	33-40
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	78-85
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	78-85
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	78-85
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	78-85
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	78-85
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	157-164	insulin like growth factor binding protein 5	Homo sapiens	33-40
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	157-164	insulin like growth factor binding protein 5	Homo sapiens	78-85
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	157-164	insulin like growth factor binding protein 5	Homo sapiens	78-85
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	157-164	insulin like growth factor binding protein 5	Homo sapiens	78-85
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	157-164	insulin like growth factor binding protein 5	Homo sapiens	78-85
9374688-6	1997	Heparin inhibited the binding of IGFBP-5 to HA and blocked the interaction of IGFBP-5 with IGFBP-5-(201-218) in the fluid phase, suggesting that the primary heparin-binding domain of IGFBP-5 specifically enhances the binding of IGFBP-5 to HA and increases IGF-I binding to IGFBP-5.	Heparin	157-164	insulin like growth factor binding protein 5	Homo sapiens	78-85
9367833-0	1997	Retinoic acid inhibits cell growth in HPV negative cervical carcinoma cells by induction of insulin-like growth factor binding protein-5 (IGFBP-5) secretion.	Tretinoin	0-13	insulin like growth factor binding protein 5	Homo sapiens	92-136
9367833-0	1997	Retinoic acid inhibits cell growth in HPV negative cervical carcinoma cells by induction of insulin-like growth factor binding protein-5 (IGFBP-5) secretion.	Tretinoin	0-13	insulin like growth factor binding protein 5	Homo sapiens	138-145
9367833-5	1997	Since RA has been shown to modulate the expression of insulin-like growth factor binding proteins (IGFBPs) in many cells, we examined RA regulated expression of IGFBPs in medium isolated from RA treated C33A cells.	Tretinoin	6-8	insulin like growth factor binding protein 5	Homo sapiens	99-105
9367833-6	1997	IGFBP-5 was detectable in medium from C33A cells exposed to RA, and addition of purified exogenous IGFBP-5 resulted in growth inhibition of C33A cells.	Tretinoin	60-62	insulin like growth factor binding protein 5	Homo sapiens	0-7
9367833-7	1997	These results indicate that RA exerts it"s anti-neoplastic effect in HPV negative cervical carcinoma cells via the overproduction of IGFBP-5.	Tretinoin	28-30	insulin like growth factor binding protein 5	Homo sapiens	133-140
9213226-3	1997	In the current study, we show that either IGFBP-3 or IGFBP-5 are the major forms of IGFBP released from monolayers of human GM10 fibroblasts, T98G glioblastoma cells and forskolin-treated bovine MDBK cells.	Colforsin	170-179	insulin like growth factor binding protein 5	Homo sapiens	53-60
9150190-10	1997	Immunoblotting experiments demonstrated that all three vitamin D-related compounds induced the accumulation of insulin-like growth factor-binding protein 5 in cell-conditioned media.	Vitamin D	55-64	insulin like growth factor binding protein 5	Homo sapiens	111-155
9150190-13	1997	CONCLUSIONS AND IMPLICATIONS: Our results indicate that vitamin D-related compounds stimulate production of insulin-like growth factor-binding protein 5, thereby indirectly suppressing cell proliferation.	Vitamin D	56-65	insulin like growth factor binding protein 5	Homo sapiens	108-152
9130463-11	1997	Both cAMP and Matrigel matrix treatment enhanced IGFBP-5 protein expression and cAMP increased IGFBP-5 gene expression five fold.	Cyclic AMP	5-9	insulin like growth factor binding protein 5	Homo sapiens	95-102
9130463-11	1997	Both cAMP and Matrigel matrix treatment enhanced IGFBP-5 protein expression and cAMP increased IGFBP-5 gene expression five fold.	Cyclic AMP	80-84	insulin like growth factor binding protein 5	Homo sapiens	95-102
9140069-2	1997	Three of these proteins-IGFBP-1, IGFBP-3 and IGFBP-5-are known to be serine-phosphorylated in their central domains, and the others have possible target sites for serine/threonine kinases.	Serine	69-75	insulin like growth factor binding protein 5	Homo sapiens	45-52
8930399-3	1996	We observed that the potent antiestrogen ICI 182780 (ICI) increased IGFBP-5 mRNA by 2-3-fold in 9,10-dimethyl-1,2-benzanthracene-induced mammary tumors in vivo.	9,10-Dimethyl-1,2-benzanthracene	96-128	insulin like growth factor binding protein 5	Homo sapiens	68-75
8940380-4	1996	The heparin Sepharose purified material degraded IGFBP-5 into 22-, 17-, and 16-kDa fragments.	Heparin	4-11	insulin like growth factor binding protein 5	Homo sapiens	49-56
8940380-4	1996	The heparin Sepharose purified material degraded IGFBP-5 into 22-, 17-, and 16-kDa fragments.	Sepharose	12-21	insulin like growth factor binding protein 5	Homo sapiens	49-56
8930399-6	1996	An IGFBP-5 antisense oligodeoxynucleotide significantly decreased IGFBP-5 accumulation in conditioned media and enhanced MCF-7 cell DNA synthesis.	Oligodeoxyribonucleotides	21-41	insulin like growth factor binding protein 5	Homo sapiens	3-10
8930399-6	1996	An IGFBP-5 antisense oligodeoxynucleotide significantly decreased IGFBP-5 accumulation in conditioned media and enhanced MCF-7 cell DNA synthesis.	Oligodeoxyribonucleotides	21-41	insulin like growth factor binding protein 5	Homo sapiens	66-73
8930399-7	1996	Furthermore, this antisense oligodeoxynucleotide attenuated both antiestrogen-induced IGFBP-5 accumulation and antiestrogen-induced growth inhibition.	Oligodeoxyribonucleotides	28-48	insulin like growth factor binding protein 5	Homo sapiens	86-93
8768874-11	1996	Steady-state levels of IGFBP-3 and IGFBP-5 messenger RNAs were elevated after treatment with transforming growth factor-beta and high TSH concentrations.	Thyrotropin	134-137	insulin like growth factor binding protein 5	Homo sapiens	35-42
8895319-4	1996	We have previously shown that IGFBP-5 associates with glycosaminoglycans and binds to proteoglycans that are contained in ECM and basement membranes.	Glycosaminoglycans	54-72	insulin like growth factor binding protein 5	Homo sapiens	30-37
8895319-10	1996	Binding was also inhibited by a synthetic IGFBP-5 peptide that contained a heparin-binding domain, but not by a peptide with an identical charge to mass ratio that does not bind to heparin.	Heparin	75-82	insulin like growth factor binding protein 5	Homo sapiens	42-49
8662813-3	1996	Synthetic peptides were prepared that were homologous with two regions of basic amino acids within IGFBP-5 (Arg201-Arg218 and Ala131-Thr141).	Amino Acids, Basic	74-91	insulin like growth factor binding protein 5	Homo sapiens	99-106
8626396-0	1996	Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin.	Heparin	98-105	insulin like growth factor binding protein 5	Homo sapiens	40-90
8664980-3	1996	In the present study of normal human osteoblast-like (HOB) cells, we tested the hypothesis that dexamethasone (Dex) inhibits IGF anabolic activity in bone by altering expression of IGF binding proteins (IGFBPs), particularly by decreasing expression of IGFBP-5 and IGFBP-3 (which enhance IGF activity) and increasing expression of IGFBP-4 (which inhibits IGF actions).	Dexamethasone	96-109	insulin like growth factor binding protein 5	Homo sapiens	253-260
8664980-3	1996	In the present study of normal human osteoblast-like (HOB) cells, we tested the hypothesis that dexamethasone (Dex) inhibits IGF anabolic activity in bone by altering expression of IGF binding proteins (IGFBPs), particularly by decreasing expression of IGFBP-5 and IGFBP-3 (which enhance IGF activity) and increasing expression of IGFBP-4 (which inhibits IGF actions).	Dexamethasone	111-114	insulin like growth factor binding protein 5	Homo sapiens	253-260
8664980-5	1996	Dexamethasone decreased IGFBP-5 mRNA levels to 20-30% of control (10(-8) and 10(-7) mol/l for 24 h).	Dexamethasone	0-13	insulin like growth factor binding protein 5	Homo sapiens	24-31
8664980-6	1996	In six of six HOB preparations, 10(-8) mol/l Dex decreased IGFBP-5 mRNA levels (35 +/- 7% of control) and this effect was time dependent.	Dexamethasone	45-48	insulin like growth factor binding protein 5	Homo sapiens	59-66
8664980-8	1996	Dexamethasone decreased secretion of 29-31-kD IGFBP-5 and 38-42-kD IGFBP-3 proteins, determined by Western ligand blot and IGFBP-5 immunoblot, and induced a dose-dependent decrease in IGFBP-3 and IGFBP-5 secretion determined by specific radioimmunoassays.	Dexamethasone	0-13	insulin like growth factor binding protein 5	Homo sapiens	46-53
8664980-8	1996	Dexamethasone decreased secretion of 29-31-kD IGFBP-5 and 38-42-kD IGFBP-3 proteins, determined by Western ligand blot and IGFBP-5 immunoblot, and induced a dose-dependent decrease in IGFBP-3 and IGFBP-5 secretion determined by specific radioimmunoassays.	Dexamethasone	0-13	insulin like growth factor binding protein 5	Homo sapiens	123-130
8664980-8	1996	Dexamethasone decreased secretion of 29-31-kD IGFBP-5 and 38-42-kD IGFBP-3 proteins, determined by Western ligand blot and IGFBP-5 immunoblot, and induced a dose-dependent decrease in IGFBP-3 and IGFBP-5 secretion determined by specific radioimmunoassays.	Dexamethasone	0-13	insulin like growth factor binding protein 5	Homo sapiens	123-130
8626396-2	1996	In the present study, mutagenesis was used to analyze the effect of substitutions for basic amino acids in the Arg201-Arg218 region of IGFBP-5 on heparin-binding and the heparin-induced affinity shift.	Amino Acids, Basic	86-103	insulin like growth factor binding protein 5	Homo sapiens	135-142
8626396-2	1996	In the present study, mutagenesis was used to analyze the effect of substitutions for basic amino acids in the Arg201-Arg218 region of IGFBP-5 on heparin-binding and the heparin-induced affinity shift.	Heparin	146-153	insulin like growth factor binding protein 5	Homo sapiens	135-142
8626396-0	1996	Substitution of specific amino acids in insulin-like growth factor (IGF) binding protein 5 alters heparin binding and its change in affinity for IGF-I response to heparin.	Heparin	163-170	insulin like growth factor binding protein 5	Homo sapiens	40-90
8626396-2	1996	In the present study, mutagenesis was used to analyze the effect of substitutions for basic amino acids in the Arg201-Arg218 region of IGFBP-5 on heparin-binding and the heparin-induced affinity shift.	Heparin	170-177	insulin like growth factor binding protein 5	Homo sapiens	135-142
8626396-1	1996	Heparin binding to insulin-like growth factor (IGF)-binding protein 5 (IGFBP-5) leads to a 17-fold decrease in its affinity for IGF-I, and a region that contains several basic amino acids (Arg201-Arg218) may be involved in this affinity shift.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	19-69
8626396-5	1996	When 10 microg/ml of heparin was added, the Ka of native IGFBP-5 decreased 17-fold, and the Ka of the K134A/R136A mutant decreased 16-fold.	Heparin	21-28	insulin like growth factor binding protein 5	Homo sapiens	57-64
8626396-9	1996	Affinity cross-linking studies showed that heparin was equipotent in inhibiting the formation of 125I-IGF-I-K134A/Rl36A mutant complexes compared to native IGFBP-5.	Heparin	43-50	insulin like growth factor binding protein 5	Homo sapiens	156-163
8626396-1	1996	Heparin binding to insulin-like growth factor (IGF)-binding protein 5 (IGFBP-5) leads to a 17-fold decrease in its affinity for IGF-I, and a region that contains several basic amino acids (Arg201-Arg218) may be involved in this affinity shift.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	71-78
8603611-7	1996	The levels of the 24-, 29- to 32-, and 38- to 42 kDa IGFBPs in the conditioned medium of RA-treated cultures increased, as determined by ligand blot analysis, whereas the amount of IGFBP-5 was reduced, as determined by RIA.	Tretinoin	89-91	insulin like growth factor binding protein 5	Homo sapiens	181-188
8603611-8	1996	Cycloheximide abolished the RA-stimulated increase in IGFBP-6 mRNA and reduced baseline IGFBP-5 mRNA levels, but did not affect RA-modulated mRNA levels of the other IGFBPs.	Cycloheximide	0-13	insulin like growth factor binding protein 5	Homo sapiens	88-95
8603611-8	1996	Cycloheximide abolished the RA-stimulated increase in IGFBP-6 mRNA and reduced baseline IGFBP-5 mRNA levels, but did not affect RA-modulated mRNA levels of the other IGFBPs.	Tretinoin	28-30	insulin like growth factor binding protein 5	Homo sapiens	88-95
8603611-9	1996	RA modestly increased the stabilities of all four IGFBP mRNAs, which could contribute to the observed increases in IGFBP-3 and IGFBP-4 mRNA levels; however, the 217% increase in the IGFBP-5 mRNA half- life in the presence of RA could not contribute to the reduction in mRNA levels.	Tretinoin	0-2	insulin like growth factor binding protein 5	Homo sapiens	182-189
8603611-9	1996	RA modestly increased the stabilities of all four IGFBP mRNAs, which could contribute to the observed increases in IGFBP-3 and IGFBP-4 mRNA levels; however, the 217% increase in the IGFBP-5 mRNA half- life in the presence of RA could not contribute to the reduction in mRNA levels.	Tretinoin	225-227	insulin like growth factor binding protein 5	Homo sapiens	182-189
8603611-11	1996	These data suggest that RA stimulated changes in IGFBP-5 and -6 mRNA levels may in part be mediated by alterations in transcription or other early posttranscription regulatory mechanisms.	Tretinoin	24-26	insulin like growth factor binding protein 5	Homo sapiens	49-56
8591997-7	1996	The conditioned medium from PTH- or PGE2-treated cultures degraded recombinant human IGFBP-5 into lower molecular weight fragments.	Dinoprostone	36-40	insulin like growth factor binding protein 5	Homo sapiens	85-92
8594875-5	1995	During regeneration following folic acid-induced acute renal failure, IGF-I, IGFBP-3, and IGFBP-5 mRNAs declined in abundance approximately two- to threefold.	Folic Acid	30-40	insulin like growth factor binding protein 5	Homo sapiens	90-97
7519608-3	1994	Heparin inhibited formation of the IGF-I.IGFBP-5 complex and also separated preformed IGF-I.IGFBP-5 complexes.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	41-48
7534698-6	1995	Dexamethasone had little effect on the IGF-induced increase in IGFBP-3, but completely blocked the increase in IGFBP-5 expression.	Dexamethasone	0-13	insulin like growth factor binding protein 5	Homo sapiens	111-118
7534698-11	1995	Dexamethasone alone decreased IGFBP-3, IGFBP-4, and IGFBP-5 mRNA, but it had no significant effect on IGFBP-3, -4, or -5 expression in the presence of IGF-I.	Dexamethasone	0-13	insulin like growth factor binding protein 5	Homo sapiens	52-59
7527332-6	1994	Heparin and heparan sulfate inhibited IGFBP-5 degradation at concentrations of 1 or 2.5 micrograms/ml, but 100 micrograms/ml dermatan sulfate were required.	Heparitin Sulfate	12-27	insulin like growth factor binding protein 5	Homo sapiens	38-45
7527332-10	1994	Dextran sulfate, pentosan polysulfate, and fucoidan, which are composed of different saccharide units but contain O-sulfate groups in the 2 or 3 carbon positions, also inhibited IGFBP-5 degradation.	Dextran Sulfate	0-15	insulin like growth factor binding protein 5	Homo sapiens	178-185
7527332-10	1994	Dextran sulfate, pentosan polysulfate, and fucoidan, which are composed of different saccharide units but contain O-sulfate groups in the 2 or 3 carbon positions, also inhibited IGFBP-5 degradation.	Pentosan Sulfuric Polyester	17-37	insulin like growth factor binding protein 5	Homo sapiens	178-185
7527332-10	1994	Dextran sulfate, pentosan polysulfate, and fucoidan, which are composed of different saccharide units but contain O-sulfate groups in the 2 or 3 carbon positions, also inhibited IGFBP-5 degradation.	fucoidan	43-51	insulin like growth factor binding protein 5	Homo sapiens	178-185
7527332-10	1994	Dextran sulfate, pentosan polysulfate, and fucoidan, which are composed of different saccharide units but contain O-sulfate groups in the 2 or 3 carbon positions, also inhibited IGFBP-5 degradation.	Carbohydrates	85-95	insulin like growth factor binding protein 5	Homo sapiens	178-185
7527332-10	1994	Dextran sulfate, pentosan polysulfate, and fucoidan, which are composed of different saccharide units but contain O-sulfate groups in the 2 or 3 carbon positions, also inhibited IGFBP-5 degradation.	o-sulfate	114-123	insulin like growth factor binding protein 5	Homo sapiens	178-185
7527332-10	1994	Dextran sulfate, pentosan polysulfate, and fucoidan, which are composed of different saccharide units but contain O-sulfate groups in the 2 or 3 carbon positions, also inhibited IGFBP-5 degradation.	Carbon	145-151	insulin like growth factor binding protein 5	Homo sapiens	178-185
7527332-13	1994	As glycosaminoglycan side-chains are present in proteoglycans that are present in extracellular matrix and on cell surfaces, these side-chains represent a potential mechanism for regulating IGFBP-5 proteolysis in vivo.	Glycosaminoglycans	3-20	insulin like growth factor binding protein 5	Homo sapiens	190-197
7519608-5	1994	Heparin exposure was associated with a 17-fold decrease in the affinity of IGFBP-5 for IGF-I.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	75-82
7519608-6	1994	A synthetic peptide that contains residues from Arg221 to Arg238 of IGFBP-5, and a heparin binding domain prevented the inhibitory effects of heparin on formation of the IGF-I.IGFBP-5 complex.	Heparin	83-90	insulin like growth factor binding protein 5	Homo sapiens	176-183
7519608-6	1994	A synthetic peptide that contains residues from Arg221 to Arg238 of IGFBP-5, and a heparin binding domain prevented the inhibitory effects of heparin on formation of the IGF-I.IGFBP-5 complex.	Heparin	142-149	insulin like growth factor binding protein 5	Homo sapiens	68-75
7559606-2	1995	IG-FBP-5 mRNA is abundant in human fibroblasts and is regulated by cAMP.	Cyclic AMP	67-71	insulin like growth factor binding protein 5	Homo sapiens	0-8
7559606-16	1995	This AP-2-mediated trans-activation contributes at least in part to the constitutively high expression of IGFBP-5 in fibroblasts and to the cAMP responsiveness of this gene.	Cyclic AMP	140-144	insulin like growth factor binding protein 5	Homo sapiens	106-113
7538463-15	1995	These data taken together with the protease inhibitor results suggest that the IGFBP-2, IGFBP-4, and IGFBP-5 proteases are members of a similar family of calcium-dependent serine proteases, but they are distinct proteases.	Calcium	154-161	insulin like growth factor binding protein 5	Homo sapiens	101-108
7538367-3	1995	Of the 6 IGFBPs, IGFBP-3 and IGFBP-5 had the greatest heparin affinity.	Heparin	54-61	insulin like growth factor binding protein 5	Homo sapiens	29-36
8817657-1	1995	The insulin-like growth factor binding proteins (IGFBPs) have conserved characteristics of their genomic organization, including similar locations of exon borders relative to nucleotides encoding conserved cysteine residues.	Cysteine	206-214	insulin like growth factor binding protein 5	Homo sapiens	49-55
8817658-2	1995	IGF I increases IGFBP-5 mRNA levels in both cell types, whereas retinoic acid stimulates IGFBP-5 mRNA expression in calvaria but suppresses it in Saos-2 cells.	Tretinoin	64-77	insulin like growth factor binding protein 5	Homo sapiens	89-96
8817658-4	1995	30 nM IGFBP-5 stimulates 3H-thymidine incorporation in calvaria (which produce IGF I contributing to basal proliferation in serum-free medium) but not in Saos-2 cells which produce little IGF I and IGF II.	Tritium	25-27	insulin like growth factor binding protein 5	Homo sapiens	6-13
8817658-4	1995	30 nM IGFBP-5 stimulates 3H-thymidine incorporation in calvaria (which produce IGF I contributing to basal proliferation in serum-free medium) but not in Saos-2 cells which produce little IGF I and IGF II.	Thymidine	28-37	insulin like growth factor binding protein 5	Homo sapiens	6-13
7527332-3	1994	In this study we investigated the effects of glycosaminoglycans on IGFBP-5 degradation in fibroblast-conditioned medium.	Glycosaminoglycans	45-63	insulin like growth factor binding protein 5	Homo sapiens	67-74
7527332-4	1994	The addition of heparin, heparan sulfate, and dermatan sulfate (100 micrograms/ml) to the medium of fibroblast monolayer cultures inhibited IGFBP-5 degradation, as determined by the conversion of intact IGFBP-5 to a 23-kilodalton fragment.	Heparin	16-23	insulin like growth factor binding protein 5	Homo sapiens	140-147
7527332-4	1994	The addition of heparin, heparan sulfate, and dermatan sulfate (100 micrograms/ml) to the medium of fibroblast monolayer cultures inhibited IGFBP-5 degradation, as determined by the conversion of intact IGFBP-5 to a 23-kilodalton fragment.	Heparin	16-23	insulin like growth factor binding protein 5	Homo sapiens	203-210
7527332-4	1994	The addition of heparin, heparan sulfate, and dermatan sulfate (100 micrograms/ml) to the medium of fibroblast monolayer cultures inhibited IGFBP-5 degradation, as determined by the conversion of intact IGFBP-5 to a 23-kilodalton fragment.	Heparitin Sulfate	25-40	insulin like growth factor binding protein 5	Homo sapiens	140-147
7527332-4	1994	The addition of heparin, heparan sulfate, and dermatan sulfate (100 micrograms/ml) to the medium of fibroblast monolayer cultures inhibited IGFBP-5 degradation, as determined by the conversion of intact IGFBP-5 to a 23-kilodalton fragment.	Heparitin Sulfate	25-40	insulin like growth factor binding protein 5	Homo sapiens	203-210
7527332-4	1994	The addition of heparin, heparan sulfate, and dermatan sulfate (100 micrograms/ml) to the medium of fibroblast monolayer cultures inhibited IGFBP-5 degradation, as determined by the conversion of intact IGFBP-5 to a 23-kilodalton fragment.	Dermatan Sulfate	46-62	insulin like growth factor binding protein 5	Homo sapiens	140-147
7527332-4	1994	The addition of heparin, heparan sulfate, and dermatan sulfate (100 micrograms/ml) to the medium of fibroblast monolayer cultures inhibited IGFBP-5 degradation, as determined by the conversion of intact IGFBP-5 to a 23-kilodalton fragment.	Dermatan Sulfate	46-62	insulin like growth factor binding protein 5	Homo sapiens	203-210
7527332-6	1994	Heparin and heparan sulfate inhibited IGFBP-5 degradation at concentrations of 1 or 2.5 micrograms/ml, but 100 micrograms/ml dermatan sulfate were required.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	38-45
7519608-6	1994	A synthetic peptide that contains residues from Arg221 to Arg238 of IGFBP-5, and a heparin binding domain prevented the inhibitory effects of heparin on formation of the IGF-I.IGFBP-5 complex.	Heparin	142-149	insulin like growth factor binding protein 5	Homo sapiens	176-183
7519608-3	1994	Heparin inhibited formation of the IGF-I.IGFBP-5 complex and also separated preformed IGF-I.IGFBP-5 complexes.	Heparin	0-7	insulin like growth factor binding protein 5	Homo sapiens	92-99
7521344-0	1993	Regulation of insulin-like growth factor (IGF) binding protein-5 in the T47D human breast carcinoma cell line by IGF-I and retinoic acid.	Tretinoin	123-136	insulin like growth factor binding protein 5	Homo sapiens	14-64
7532465-8	1994	However, in the same samples, IGFBP 5 expression was inhibited by RU 486, and RU 486 was unable to reverse the effects of progestins on the expression of IGFBP 5.	Mifepristone	66-72	insulin like growth factor binding protein 5	Homo sapiens	30-37
7506211-10	1994	Both IGFBP-4 and IGFBP-5 proteolytic activities were inhibited by aprotinin, zinc chloride, and EDTA and eluted as a single major peak between mol wt markers of 160 and 67 kDa upon gel filtration.	zinc chloride	77-90	insulin like growth factor binding protein 5	Homo sapiens	17-24
7506211-10	1994	Both IGFBP-4 and IGFBP-5 proteolytic activities were inhibited by aprotinin, zinc chloride, and EDTA and eluted as a single major peak between mol wt markers of 160 and 67 kDa upon gel filtration.	Edetic Acid	96-100	insulin like growth factor binding protein 5	Homo sapiens	17-24
7521344-9	1993	The inhibitory effect of RA, on the other hand, appears to be due primarily to regulation of IGFBP-5 mRNA levels.	Tretinoin	25-27	insulin like growth factor binding protein 5	Homo sapiens	93-100
35178407-13	2021	GSEA indicated that IGFBP5 might involve in the synthesis of myosin complex, participate in kinesin binding, motor activity and function via the regulation of actin cytoskeleton.	gsea	0-4	insulin like growth factor binding protein 5	Homo sapiens	20-26
7684042-12	1993	The addition of RA also blocked IGF-I stimulation of IGFBP-2 and IGFBP-5 levels.	Tretinoin	16-18	insulin like growth factor binding protein 5	Homo sapiens	65-72
7684042-13	1993	Cycloheximide treatment completely blocked the RA and/or IGF-I-mediated modulation of these binding proteins, suggesting that these agents enhance IGFBP-3, IGFBP-2, and IGFBP-5 synthesis and consequent secretion.	Cycloheximide	0-13	insulin like growth factor binding protein 5	Homo sapiens	169-176
7683536-4	1993	Recent studies suggest that IGFs are fixed in bone by means of IGFBP-5 which binds with high affinity to both hydroxyapatite and IGFs.	Durapatite	110-124	insulin like growth factor binding protein 5	Homo sapiens	63-70
1280130-0	1992	Insulin-like growth factor binding protein-5 gene expression is differentially regulated at a post-transcriptional level in retinoic acid-sensitive and resistant MCF-7 human breast carcinoma cells.	Tretinoin	124-137	insulin like growth factor binding protein 5	Homo sapiens	0-44
1280130-4	1992	Actinomycin D and cycloheximide differentially stabilized IGFBP-5 mRNA in MCF-7 cells but not in RRO-I cells, indicating a difference in the control of IGFBP-5 gene regulation at the level of mRNA stability in these cell lines.	Dactinomycin	0-13	insulin like growth factor binding protein 5	Homo sapiens	58-65
1280130-4	1992	Actinomycin D and cycloheximide differentially stabilized IGFBP-5 mRNA in MCF-7 cells but not in RRO-I cells, indicating a difference in the control of IGFBP-5 gene regulation at the level of mRNA stability in these cell lines.	Dactinomycin	0-13	insulin like growth factor binding protein 5	Homo sapiens	152-159
1280130-4	1992	Actinomycin D and cycloheximide differentially stabilized IGFBP-5 mRNA in MCF-7 cells but not in RRO-I cells, indicating a difference in the control of IGFBP-5 gene regulation at the level of mRNA stability in these cell lines.	Cycloheximide	18-31	insulin like growth factor binding protein 5	Homo sapiens	58-65
1280130-4	1992	Actinomycin D and cycloheximide differentially stabilized IGFBP-5 mRNA in MCF-7 cells but not in RRO-I cells, indicating a difference in the control of IGFBP-5 gene regulation at the level of mRNA stability in these cell lines.	Cycloheximide	18-31	insulin like growth factor binding protein 5	Homo sapiens	152-159
7683690-6	1993	Increasing salt concentrations inhibited the binding of IGFBP-5 to ECM and accelerated the release of IGFBP-5 from ECM, suggesting an ionic basis for this interaction.	Salts	11-15	insulin like growth factor binding protein 5	Homo sapiens	56-63
7683690-6	1993	Increasing salt concentrations inhibited the binding of IGFBP-5 to ECM and accelerated the release of IGFBP-5 from ECM, suggesting an ionic basis for this interaction.	Salts	11-15	insulin like growth factor binding protein 5	Homo sapiens	102-109
35274778-0	2022	hsa_circ_0058122 knockdown prevents steroid-induced osteonecrosis of the femoral head by inhibiting human umbilical vein endothelial cells apoptosis via the miR-7974/IGFBP5 axis.	Steroids	36-43	insulin like growth factor binding protein 5	Homo sapiens	166-172
32771300-0	2020	Involvement of the lipoprotein receptor LRP1 in AMP-IBP5-mediated migration and proliferation of human keratinocytes and fibroblasts.	Adenosine Monophosphate	48-51	insulin like growth factor binding protein 5	Homo sapiens	52-56
33010605-0	2020	MiR-193b inhibits autophagy and apoptosis by targeting IGFBP5 in high glucose-induced trophoblasts.	Glucose	70-77	insulin like growth factor binding protein 5	Homo sapiens	55-61
32585423-0	2020	Quercetin induces apoptosis in meningioma cells through the miR-197/IGFBP5 cascade.	Quercetin	0-9	insulin like growth factor binding protein 5	Homo sapiens	68-74
32585423-7	2020	Quercetin treatment also decreases Bcl-2 and increases Bax protein expression, and increases miR-197 mRNA while reducing IGFBP5 mRNA expression.	Quercetin	0-9	insulin like growth factor binding protein 5	Homo sapiens	121-127
32585423-9	2020	Quercetin may reduce meningioma cell proliferation and increase apoptosis by activating the miR-197/IGFBP5 cascade and regulating Bcl-2/Bax.	Quercetin	0-9	insulin like growth factor binding protein 5	Homo sapiens	100-106
32771300-3	2020	OBJECTIVES: To investigate whether LRP1 is involved in AMP-IBP5-induced migration and proliferation of human epidermal keratinocytes and dermal fibroblasts.	Adenosine Monophosphate	55-58	insulin like growth factor binding protein 5	Homo sapiens	59-63
32771300-8	2020	RESULTS: We found that AMP-IBP5 markedly induced the migration and proliferation of keratinocytes and fibroblasts, and this effect was reversed by specific siRNA and neutralizing antibody targeting the LRP1 receptor.	Adenosine Monophosphate	23-26	insulin like growth factor binding protein 5	Homo sapiens	27-31
32771300-9	2020	In addition, LRP1 was upregulated by lipopolysaccharide, flagellin and AMP-IBP5 in keratinocytes and fibroblasts.	Adenosine Monophosphate	71-74	insulin like growth factor binding protein 5	Homo sapiens	75-79
32771300-11	2020	CONCLUSIONS: Our results suggest that LRP1 expressed in human epidermal keratinocytes and dermal fibroblasts contributes to AMP-IBP5-mediated cell migration and proliferation, supporting its crucial role in cutaneous wound healing process.	Adenosine Monophosphate	124-127	insulin like growth factor binding protein 5	Homo sapiens	128-132
32843583-4	2020	Expression of a newly identified target of Y-27632 by RNA-seq, insulin growth factor binding protein 5 (IGFBP-5), was dramatically increased after 24 h of treatment with Y-27632.	Y 27632	43-50	insulin like growth factor binding protein 5	Homo sapiens	63-102
32585242-10	2020	IGFBP5 overexpression reduced levels of lipogenesis-associated proteins (SREBP-1c, FAS and ACC1), elevated expression of fatty acid beta-oxidation-related genes (PPARalpha, CPT1A and ACOX1), decreased intracellular lipid droplets, promoted glucose uptake and glycogenesis, and activated IRS1/Akt and AMPK pathways.	Fatty Acids	121-131	insulin like growth factor binding protein 5	Homo sapiens	0-6
32585242-10	2020	IGFBP5 overexpression reduced levels of lipogenesis-associated proteins (SREBP-1c, FAS and ACC1), elevated expression of fatty acid beta-oxidation-related genes (PPARalpha, CPT1A and ACOX1), decreased intracellular lipid droplets, promoted glucose uptake and glycogenesis, and activated IRS1/Akt and AMPK pathways.	Glucose	240-247	insulin like growth factor binding protein 5	Homo sapiens	0-6
32843583-0	2020	Prolonged treatment with Y-27632 promotes the senescence of primary human dermal fibroblasts by increasing the expression of IGFBP-5 and transforming them into a CAF-like phenotype.	Y 27632	25-32	insulin like growth factor binding protein 5	Homo sapiens	125-132
32843583-4	2020	Expression of a newly identified target of Y-27632 by RNA-seq, insulin growth factor binding protein 5 (IGFBP-5), was dramatically increased after 24 h of treatment with Y-27632.	Y 27632	43-50	insulin like growth factor binding protein 5	Homo sapiens	104-111
32843583-4	2020	Expression of a newly identified target of Y-27632 by RNA-seq, insulin growth factor binding protein 5 (IGFBP-5), was dramatically increased after 24 h of treatment with Y-27632.	Y 27632	170-177	insulin like growth factor binding protein 5	Homo sapiens	63-102
32843583-4	2020	Expression of a newly identified target of Y-27632 by RNA-seq, insulin growth factor binding protein 5 (IGFBP-5), was dramatically increased after 24 h of treatment with Y-27632.	Y 27632	170-177	insulin like growth factor binding protein 5	Homo sapiens	104-111
32843583-5	2020	Adding recombinant IGFBP-5 protein to the culture medium produced similar phenotypes of HDFs as did treatment with Y-27632, and knockdown of IGFBP-5 blocked the Y-27632-induced senescence.	Y 27632	161-168	insulin like growth factor binding protein 5	Homo sapiens	19-26
32843583-5	2020	Adding recombinant IGFBP-5 protein to the culture medium produced similar phenotypes of HDFs as did treatment with Y-27632, and knockdown of IGFBP-5 blocked the Y-27632-induced senescence.	Y 27632	161-168	insulin like growth factor binding protein 5	Homo sapiens	141-148
32843583-6	2020	Furthermore, Y-27632 induced the expression of an IGFBP-5 upstream gene, GATA4, and knockdown of GATA4 also reduced the Y-27632-induced senescence.	Y 27632	13-20	insulin like growth factor binding protein 5	Homo sapiens	50-57
32843583-6	2020	Furthermore, Y-27632 induced the expression of an IGFBP-5 upstream gene, GATA4, and knockdown of GATA4 also reduced the Y-27632-induced senescence.	Y 27632	120-127	insulin like growth factor binding protein 5	Homo sapiens	50-57
32843583-7	2020	In summary, these results demonstrate for the first time that Y-27632 promotes cellular senescence in primary HDFs by inducing the expression of IGFBP-5 and that prolonged treatment with Y-27632 potentially transforms primary HDFs into CAF-like cells.	Y 27632	62-69	insulin like growth factor binding protein 5	Homo sapiens	145-152
31103062-9	2019	In vitro DHT stimulation increased AR-45 protein and IGF-1R and IGFBP-5 mRNA expression.	Dihydrotestosterone	9-12	insulin like growth factor binding protein 5	Homo sapiens	64-71
33455368-7	2020	The supernatant from a culture of RAW 264.7 stimulated by COS(4) and COS5 [conditioned medium S-COS(4) and S-COS5] contained more osteogenesis- and angiogenesis-related proteins like DKK-1, OPN, osteoactivin, vascular endothelial growth factor (VEGF) R1, epidermal growth factor (EGF), and insulin-like growth factor binding protein-5 (IGFBP-5) for regulation of osteogenesis/angiogenesis.	oligochitosan	58-61	insulin like growth factor binding protein 5	Homo sapiens	290-334
33455368-7	2020	The supernatant from a culture of RAW 264.7 stimulated by COS(4) and COS5 [conditioned medium S-COS(4) and S-COS5] contained more osteogenesis- and angiogenesis-related proteins like DKK-1, OPN, osteoactivin, vascular endothelial growth factor (VEGF) R1, epidermal growth factor (EGF), and insulin-like growth factor binding protein-5 (IGFBP-5) for regulation of osteogenesis/angiogenesis.	oligochitosan	58-61	insulin like growth factor binding protein 5	Homo sapiens	336-343
31549646-11	2019	mRNA transcripts of ATP5A1, GADD45A, IGFBP5, SOD1, STMN1 genes were prominently upregulated providing candid evidence on TCP mediated activation of human cancer pathways to orchestrate the apoptotic death of HepG2 cells, specifying hepatotoxic potential of TCP.	Tritolyl Phosphates	121-124	insulin like growth factor binding protein 5	Homo sapiens	37-43
31109829-6	2019	The molecular mechanism of Mybbp1a regulating IGFBP5 was proved through CO-IP, CHIP, Bisulfite Sequencing and Pyrosequencing.	hydrogen sulfite	85-94	insulin like growth factor binding protein 5	Homo sapiens	46-52
31519945-5	2019	The serine variant also showed a trend towards reduced cleavage rates, that was not significant, towards IGFBP-2 and IGFBP-5 compared to the tyrosine variant.	Serine	4-10	insulin like growth factor binding protein 5	Homo sapiens	117-124
31290273-5	2019	IGFBP5 was shown to significantly promote NP cell proliferation and inhibit apoptosis in vitro, which was confirmed by MTT, flow cytometry and colony formation assays.	monooxyethylene trimethylolpropane tristearate	119-122	insulin like growth factor binding protein 5	Homo sapiens	0-6
30241323-0	2018	Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma.	Cisplatin	77-86	insulin like growth factor binding protein 5	Homo sapiens	60-66
30810066-0	2019	NADPH oxidase-mediated induction of reactive oxygen species and extracellular matrix deposition by insulin-like growth factor binding protein-5.	Oxygen	45-51	insulin like growth factor binding protein 5	Homo sapiens	99-143
30810066-3	2019	Recent reports have shown a substantial role of reactive oxygen species (ROS) in fibrosis; thus we hypothesized that IGFBP-5 induces production of ROS to mediate the profibrotic process.	Reactive Oxygen Species	48-71	insulin like growth factor binding protein 5	Homo sapiens	117-124
30810066-3	2019	Recent reports have shown a substantial role of reactive oxygen species (ROS) in fibrosis; thus we hypothesized that IGFBP-5 induces production of ROS to mediate the profibrotic process.	Reactive Oxygen Species	73-76	insulin like growth factor binding protein 5	Homo sapiens	117-124
30810066-3	2019	Recent reports have shown a substantial role of reactive oxygen species (ROS) in fibrosis; thus we hypothesized that IGFBP-5 induces production of ROS to mediate the profibrotic process.	Reactive Oxygen Species	147-150	insulin like growth factor binding protein 5	Homo sapiens	117-124
30810066-4	2019	In vitro analyses revealed that ROS production was induced by recombinant and adenoviral vector-mediated IGFBP-5 (AdBP5) in a dose- and time-dependent manner, regulated through MEK/ERK and JNK signaling, and primarily mediated by NADPH oxidase (Nox).	Reactive Oxygen Species	32-35	insulin like growth factor binding protein 5	Homo sapiens	105-112
30810066-5	2019	Silencing IGFBP-5 in SSc and IPF fibroblasts reduced ROS production.	Reactive Oxygen Species	53-56	insulin like growth factor binding protein 5	Homo sapiens	10-17
30810066-6	2019	The antioxidants diphenyleneiodonium and N-acetylcysteine blocked IGFBP-5-stimulated ECM production in normal, SSc, and IPF human primary lung fibroblasts.	diphenyleneiodonium	17-36	insulin like growth factor binding protein 5	Homo sapiens	66-73
30810066-6	2019	The antioxidants diphenyleneiodonium and N-acetylcysteine blocked IGFBP-5-stimulated ECM production in normal, SSc, and IPF human primary lung fibroblasts.	Acetylcysteine	41-57	insulin like growth factor binding protein 5	Homo sapiens	66-73
30810066-8	2019	IGFBP-5 stimulated transcriptional expression of Nox3 in human fibroblasts while selective knockdown of Nox3 reduced ROS production by IGFBP-5.	Reactive Oxygen Species	117-120	insulin like growth factor binding protein 5	Homo sapiens	135-142
30810066-9	2019	Thus IGFBP-5 mediates fibrosis through production of ROS in a Nox-dependent manner.	Reactive Oxygen Species	53-56	insulin like growth factor binding protein 5	Homo sapiens	5-12
30684263-0	2019	IGFBP5 suppresses oleate-induced intramyocellular lipids deposition and enhances insulin signaling.	Oleic Acid	18-24	insulin like growth factor binding protein 5	Homo sapiens	0-6
30684263-4	2019	Then, we added exogenous recombinant IGFBP5 during myocyte triglyceride (TAG) formation and found decreased lipids accumulation.	Triglycerides	59-71	insulin like growth factor binding protein 5	Homo sapiens	37-43
30684263-7	2019	Meanwhile, IGFBP5 also inhibited the expression of glycerol-3-phosphate acyltransferase (GPAM) and diglyceride acyltransferase 2 (DGAT2), which were involved in TAG synthesis from a fatty acid.	Fatty Acids	182-192	insulin like growth factor binding protein 5	Homo sapiens	11-17
30241323-0	2018	Expression of Insulin-Like Growth Factor Binding Protein-5 (IGFBP5) Reverses Cisplatin-Resistance in Esophageal Carcinoma.	Cisplatin	77-86	insulin like growth factor binding protein 5	Homo sapiens	14-58
30241323-11	2018	Suppression of IGFBP5 mediated by IGFBP5-targeting siRNA in parental SLMT-1 cells confirmed that IGFBP5 suppression in ESCC cells would induce CDDP-resistance.	Cisplatin	143-147	insulin like growth factor binding protein 5	Homo sapiens	15-21
30241323-11	2018	Suppression of IGFBP5 mediated by IGFBP5-targeting siRNA in parental SLMT-1 cells confirmed that IGFBP5 suppression in ESCC cells would induce CDDP-resistance.	Cisplatin	143-147	insulin like growth factor binding protein 5	Homo sapiens	34-40
30241323-11	2018	Suppression of IGFBP5 mediated by IGFBP5-targeting siRNA in parental SLMT-1 cells confirmed that IGFBP5 suppression in ESCC cells would induce CDDP-resistance.	Cisplatin	143-147	insulin like growth factor binding protein 5	Homo sapiens	34-40
30241323-12	2018	More importantly, upregulation of IGFBP5 using IGFBP5 expression vector reduced cisplatin-resistance in SLMT-1/CDDP1R cells by 41%.	Cisplatin	80-89	insulin like growth factor binding protein 5	Homo sapiens	34-40
30241323-12	2018	More importantly, upregulation of IGFBP5 using IGFBP5 expression vector reduced cisplatin-resistance in SLMT-1/CDDP1R cells by 41%.	Cisplatin	80-89	insulin like growth factor binding protein 5	Homo sapiens	47-53
30241323-13	2018	Thus, our results demonstrated that IGFBP5 suppression is one of the mechanisms for the acquisition of cisplatin-resistance in ESCC cells.	Cisplatin	103-112	insulin like growth factor binding protein 5	Homo sapiens	36-42
30241323-14	2018	Cisplatin-resistance phenotype can be reversed by increasing the expression level of IGFBP5.	Cisplatin	0-9	insulin like growth factor binding protein 5	Homo sapiens	85-91
29939784-3	2018	Insulin-like growth factor binding protein (IGFBP5) is a proapoptotic factor that mediates Meth-induced neuronal apoptosis, and Trib3 (tribbles pseudokinase 3) is an endoplasmic reticulum (ER) stress-inducible gene involved in autophagic cell death through the mammalian target of rapamycin (mTOR) signaling pathway.	Methamphetamine	91-95	insulin like growth factor binding protein 5	Homo sapiens	44-50
29925528-5	2018	Moreover, the IGFBP5 expression is upregulated upon acquired resistance to the PI3K inhibitor GDC-0941, which is associated with an epigenetic switch from H3K27me3 to H3K27Ac at the IGFBP5 gene promoter.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	94-102	insulin like growth factor binding protein 5	Homo sapiens	14-20
29925528-5	2018	Moreover, the IGFBP5 expression is upregulated upon acquired resistance to the PI3K inhibitor GDC-0941, which is associated with an epigenetic switch from H3K27me3 to H3K27Ac at the IGFBP5 gene promoter.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	94-102	insulin like growth factor binding protein 5	Homo sapiens	182-188
29925528-6	2018	Intriguingly, GDC-0941-resistant breast cancer cells remained sensitive to KDM6B or IGFBP5 inhibition, indicating the dependency on the KDM6B-IGFBP5 axis to confer the survival advantage in GDC-0941-resistant cells.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	14-22	insulin like growth factor binding protein 5	Homo sapiens	84-90
29925528-6	2018	Intriguingly, GDC-0941-resistant breast cancer cells remained sensitive to KDM6B or IGFBP5 inhibition, indicating the dependency on the KDM6B-IGFBP5 axis to confer the survival advantage in GDC-0941-resistant cells.	2-(1H-indazol-4-yl)-6-(4-methanesulfonylpiperazin-1-ylmethyl)-4-morpholin-4-ylthieno(3,2-d)pyrimidine	14-22	insulin like growth factor binding protein 5	Homo sapiens	142-148
28554590-11	2017	AMP-IBP5-induced keratinocyte activation was mediated by Mrg X1-X4 receptors with MAPK and NF-kappaB pathways working downstream, as evidenced by the inhibitory effects of MrgX1-X4 siRNAs and ERK-, JNK-, p38- and NF-kappaB-specific inhibitors.	Adenosine Monophosphate	0-3	insulin like growth factor binding protein 5	Homo sapiens	4-8
28554590-12	2017	We confirmed that AMP-IBP5 indeed induced MAPK and NF-kappaB activation.	Adenosine Monophosphate	18-21	insulin like growth factor binding protein 5	Homo sapiens	22-26
28554590-13	2017	Furthermore, AMP-IBP5-induced VEGF but not IL-8 production correlated with an increase in intracellular cAMP.	Cyclic AMP	104-108	insulin like growth factor binding protein 5	Homo sapiens	17-21